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The Role of Hiwi in Stem Cell Maintenance and in Sarcomagenesis 
Sara Siddiqi 
 
Sarcomas are cancers of connective tissues, such as bone, adipose and cartilage, and 
are thought to arise from the aberrant development of the mesenchyme.  As such, 
mesenchymal stem cells are thought to be the cell of origin for sarcomas.  Genetic or epigenetic 
lesions at particular points during the differentiation of a mesenchymal stem cell into its terminal 
mesenchymal cell type are able to give rise to specific subtypes of sarcomas.    
Recently, a number of reports have identified elevated expression of the human Piwi 
homolog—called Hiwi—in a variety of human cancers, including gastric cancer, pancreatic 
cancer, gliomas and, most relevant for this dissertation, sarcomas.  In sarcomas, Hiwi is highly 
expressed and elevated Hiwi prognosticates shorter patient survival.     
Hiwi is the human homolog of the Piwi family of proteins, which are members of the Paz-
Piwi Doman (PPD) family.  During normal development, Piwis are thought to maintain stem cells 
of the germline, and indeed their expression is limited to early development and to the adult 
germline.  Piwis are thought to maintain stem cells in the germline with small RNA partners, 
called piwi-interacting RNAs (piRNAs).  More specifically, Piwi/piRNA complexes in the germline 
are thought to maintain transposon silencing, and thus ensure genomic stability.  A detailed 
mechanism by with Piwis suppress transposon migration in the germline remains an area of 
active investigation, but is thought to occur via DNA methylation of transposon regions.  In this 
way, Piwis are critical for maintenance of genomic integrity of germline stem cells during normal 
development.  Thus, the finding that Piwis are elevated in human cancers is directly in conflict 
with its known role in ensuring genomic stability during development.   
Piwi homologs are critical for maintenance of germline stem cells during development 
but aberrant Hiwi expression has also been identified in all cancers examined, including in 
sarcomas.  A potential connection between mesenchymal stem cells, sarcomas and Hiwi 
remains unexplored. Moreover, the role of Hiwi in sarcomas is unknown.    
In the studies presented here, we demonstrate that over-expressing Hiwi in 
mesenchymal stem cells inhibits their differentiation in vitro and generates sarcomas in vivo.  
Secondly, transgenic mice expressing Hiwi (mesodermally-restricted) develop sarcomas.  
Conversely, inducible down-regulation of Hiwi in human sarcomas inhibits growth and re-
establishes differentiation.  These data reveal that Hiwi is directly tumorigenic.  We have also 
identified the presence of piRNAs in our Hiwi-expressing models.  We further show that DNA 
methylation correlates with Hiwi expression and that cyclin-dependent kinase inhibitor (CDKI) 
tumor suppressor genes are silenced upon Hiwi over-expression.  Moreover, Hiwi’s tumorigenic 
effects are reversible using DNA de-methylating agents.     
These studies reveal for the first time not only a novel oncogenic role for Hiwi as a driver 
of tumorigenesis, but also suggest that the use of epigenetic agents may be clinically beneficial 
for treatment of tumors that express Hiwi. Additionally, our data showing that Hiwi-associated 
DNA hyper-methylation with subsequent genetic and epigenetic changes favoring a tumorigenic 
state reconciles the conundrum of how Hiwi may act appropriately to promote genomic integrity 
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1. Chapter 1: Introduction 
Sarcomas and mesenchymal stem cells 
Adult tissue stem cells are multipotent stem cells that reside in various tissues of the 
body throughout life and are able to differentiate into a limited number of specialized tissue 
types. Included in this group are mesenchymal stem cells (MSCs), which are multipotent cells 
that can divide to both self-renew and differentiate into various connective tissue lineages such 
as adipocytic, osteocytic, myocytic and chondrocytic lineages [4]. MSCs can be found in various 
parts of the body, including bone marrow, muscle and fat [5]. MSCs from bone marrow have 
been identified as non-hematopoietic stem cells by the lack of hematopoietic lineage markers 
CD14, CD34 and CD45 [6].  MSCs have been shown to propagate in vitro for several passages 
without differentiating [7] though they lose their differentiation capacity with prolonged culture in 
vitro.   
A growing body of evidence implicates MSCs as a potential cell of origin during the 
process of sarcomagenesis.  Sarcoma subtype Malignant Fibrous Histiocytoma (MFH; now 
called High Grade Undifferentiated Sarcoma [HGUS] [8]) can be derived from human MSCs [9] 
and MFH gene expression profiling parallels that of MSCs.  Moreover, inhibition of 
developmental signaling pathways in MSCs transforms them to form MFH-like tumors in vivo.   
Conversely, re-establishment of this stem cell developmental signaling in MFH cells allows them 
to re-establish differentiation capacity down typical mesenchymal lineages.  Additionally, 
specific liposarcoma subtypes have been linked with specific points in adipocytic differentiation 
of MSCs [10], suggesting a direct relationship between stage of MSC maturation arrest and 
sarcoma tumor subtype.  This allows for the categorization of sarcomas from stem cell to 





hematopoietic stem cell differentiation and lymphomagenesis [11].  Specific points of temporal 
differentiation along the adipocytic lineage yield gene expression patterns that correspond to 
poorly differentiated (de-differentiated) and well-differentiated liposarcoma subtypes.   
Aberrant MSC differentiation has also been implicated in osteosarcoma formation 
[12,13,14].  Bone formation is dependent on proper coordination between proliferation and 
differentiation.  Jain, et al showed that brief inactivation of the myc oncogene in a conditional 
transgenic mouse model of osteosarcoma resulted in regression of the tumor and differentiation 
of the tumor cells into mature osteocytes [15].  Moreover, re-activation of myc induces 
apoptosis, rather than restoring tumorigenicity.  These data suggest that even brief inactivation 
of an oncogene might alter the genetic and epigenetic context of the cell, rendering terminally 
differentiated osteocytes less permissive for tumorigenesis than MSCs.   
 The theory that the inappropriate differentiation of adult tissue stem cells can lead to 
tumor formation is not a paradigm limited only to mesenchymal stem cells and sarcomas. In 
fact, a similar concept has been thoroughly examined in hematopoietic stem cells (HSCs).  
HSCs differentiate into all blood cell types and have been historically well-studied.  There is 
considerable evidence that blood cancers such as leukemia and lymphoma arise from the 
aberrant differentiation of HSCs [reviewed in 16].  Cell surface antigen profiles of hematological 
malignancies match those of their progenitor cells at various maturation stages [17].  
Additionally, murine transplantation experiments in which leukemias can be initiated from HSC 
and from more differentiated myeloid progenitors [18] suggests that blood cancer is derived 
from an adult tissue progenitor population.  Similarly, the hypothesis of HSCs as the cell of 
origin of blood cancers may apply as well to other adult stem cells as the cell of origin for solid 





Taken together, these various studies suggest that MSCs may be the cell of origin of 
some sarcoma tumors, just as HSCs have been implicated in blood cancers [11].  Inappropriate 
MSC differentiation, as controlled by both genetic assaults and epigenetic modifications, may 
result in tumor formation.  Transformation of a MSC at a specific point in its differentiation down 
a particular mesenchymal lineage is able to give rise to a corresponding sarcoma subtype 
(Figure 1.1, adapted from [1]). 
 
The genetic and epigenetic changes that occur during the differentiation of stem cells 
can be studied using mesenchymal stem cells (MSCs) in vitro.  The well-characterized in vitro 
differentiation of MSCs can be tracked with relative ease in the laboratory.  Additionally, their 
 
Figure 1.1 Differentiating MSCs transform to develop specific sarcoma subtypes 
Transformation of a MSC during its differentiation down a particular mesenchymal lineage 






corresponding cancer, sarcomas, serve as an excellent solid tumor model, both in vitro and in 
vivo, for examining the genetic lesions and/or chromatin changes which occur during 
tumorigenesis. 
Stem cell genes in sarcomas 
Global alterations found in many cancers include hypomethylation of DNA [19] and 
hypoacetylation of histones.  In addition to gene-specific hypermethylation of DNA, these 
alterations lead to oncogene activation (R-ras, cyclin D2) and tumor suppressor silencing (RB1, 
p16).  Cancer has both a genetic and epigenetic basis, where the latter can serve as an 
alternative to genetic modification.  It is possible that in cancer, reversible epigenetic gene 
repression is replaced by aberrant permanent silencing.  Furthermore, if the altered cancer cell 
is an early progenitor cell, then it is locked in a state of perpetual (and aberrant) self-renewal.   
A variety of genetic and epigenetic lesions occur during the transformation of MSCs to 
become sarcomagenic.    Recent report finds that K-Ras expression and p16 disruption in 
discrete subsets of skeletal muscle progenitors gives rise to distinct subtypes of sarcomas [20].  
Moreover, gene expression profiling shows that oncogenes such as Ras are disrupted in both 
murine and human sarcomas.   P53 and Rb1 deficiencies are also commonly found in 
sarcomas, and MSCs have been confirmed as a preferred target for initiation of sarcomas with 
these deficiencies, in line with our previous data implicating MSCs as the cell of origin for 
sarcomas [21].  The Ewings sarcoma tumor subtype is usually associated with a EWS-FLI 
fusion gene and this fusion is thought to induce expression of embryonic stem cell genes Oct4, 
Sox2 and Nanog in pediatric MSCs [22].    Taken together, these data implicate a variety of 
genetic alterations in the initiation and progression of sarcomas, including many stem cell-





Specific epigenetic alterations correlate with sarcoma tumors as well, though more 
studies are needed to thoroughly understand the role of combinations of chromatin markers on 
tumor progression. Sarcomas show disruption of wildtype, non-tumor DNA methylation patterns.  
In vitro work has shown that osteosarcoma cell lines display aberrant DNA hyper- and hypo-
methylation [23].  We have previously shown that epigenetic changes are important for sarcoma 
differentiation [9].  Sequential chromatin immunoprecipitation (ChIP) experiments reveal that 
MSCs differentiated along the osteogenic lineage contain me-H3K4, the classical active 
chromatin mark, at the promoter regions of both c-myc and cyclin D1 (downstream Wnt/β-
catenin signaling targets) bound to β-catenin.  Wnt/β-catenin signaling promotes osteogenic 
differentiation [24], in agreement with this active me-H3K4 chromatin mark.  Additionally, MFH 
cells with re-established stem cell developmental signaling that are differentiated along the 
osteogenic lineage reveal the presence of the active chromatin mark. This is similar to MSCs 
differentiated along the same lineage, suggesting that MFH cells may originate from MSCs and 
could be re-directed along a terminal cell lineage to regain wildtype chromatin patterns.  
Conversely, Wnt/β-catenin signaling is known to be inhibitory for adipocytic differentiation [25], 
and in MSCs differentiated along this lineage, the promoter region of cyclin D1 bound to β-
catenin contains the repressive me-H3K27 mark and loses the active me-H3K4 mark.  Taken 
together, these results indicate that sarcomas have distinct epigenetic marks which can be 
modified not only to differentiate them into mesenchymal lineages but also to recapitulate 
wildtype chromatin patterns on target genes.   
While certain epigenetic chromatin modifications, such as DNA and histone methylation, 
have been studied in sarcomas, there are still additional chromatin marks that remain 
unexplored. Importantly, histone acetylation in sarcomas has yet to be thoroughly explored and 
will certainly yield greater insights into the epigenetic implications of sarcoma development and 





expression of stem cell genes.  In line with this, the Piwi family of stem cell maintenance 
genes has recently been found to be highly expressed in soft tissue sarcomas [26,27], 
perhaps locking a sarcoma progenitor cell in a state of perpetual (and aberrant) stem-like 
self renewal.   
Piwi proteins  
The role of Piwis during development 
Piwi family proteins have been studied in a variety of model organisms, including fly (Piwi), 
mouse (Miwi), and human (Hiwi) models.  Organisms in which Piwi family members have been 
identified are listed in Figure 1.2, including Piwi homolog names.   Across model systems 
examined, Piwi family member expression is largely limited to the germline (with the exception 
of one report which finds Hiwi in human hematopoietic progenitors [28]) [2,29,30].  In the 
germline, Piwis are thought to be essential for stem cell self-renewal.  The founding member of 
the Piwi-subfamily was identified in Drosophila in a transposon-mediated random gene 
disruption strategy (i.e., single P element enhancer-trap) designed to unmask genes involved in 
germ stem cell division [31]. A specific group of male Drosophila showed small testes and the 
gene responsible was termed “P-element induced wimpy” testes – Piwi. On further analysis, 
both male and female Drosophila sterile mutant gonads with inactive piwi exhibited a failure of 
germ stem cell division suggesting that piwi function is required to maintain and/or allow for 
germline stem cell division and differentiation. Conversely, over-expression of Piwi in the soma 
expands the stem cell domain and increases stem cell numbers [32,33].  Piwi has been 
detected in ovarian germline cells as well as somatic cells that maintain germ stem cell identity 
in testes [32,34,35,36]. These data indicate that somatic piwi regulates germ stem cell division 
via an intercellular mechanism and raises the possibility that Piwi may affect even somatic stem 





Down-regulation of Prg-1, the C. elegans homolog of Piwi, results in decreased germline 
stem cell proliferation and decreased fertility [32,33].  The Zebrafish Piwi homologue Ziwi is 
detectable in both testes and ovaries and loss of Ziwi results in loss of germ cells [37].  Zili, the 
other Piwi homolog in Zebrafish, is expressed in primordial germ cells of the developing embryo 
[38].  The Arabidopsis (plant) Piwi homologue, Zwille, is critical for shoot meristem self-
perpetuation [39,40,41]. The Planarians (flat worms) have three Piwi homologues-- Smedwi-1, 
Smedwi-2, and Smedwi-3 --expressed mainly in neoblasts (planarian somatic stem cells). 
Down-regulation of Smedwi-2 and Smedwi-3 blocks all cellular regeneration, not just that of 
germ cells. [42,43]. Loss of Mili and Miwi, mouse orthologs of Piwi, in transgenic mouse models 
results in a complete spermatogenesis block [44,45].  Taken together, these data suggest that 
across model organisms, Piwi proteins are essential for stem cell maintenance (both somatic 
and germ cell). 
 
 
Figure 1.2 Piwi homologs across organisms 
Piwi homologs are present in a variety of model organisms, including plants and primitive 
flatworms.  This non-exhaustive list includes names of known homologs within an organism.  





Mechanisms of Piwis 
Structurally, Piwis are members of the Paz-Piwi Domain (PPD) family.  PPD family 
members share a central Paz domain, which is a small RNA binding domain, and a C-terminal 
Piwi domain, which is catalytic and anchors the 5’ end of guide RNA.  The PPD family is divided 
into the Ago and Piwi subfamilies (Figure 1.3, adapted from [2]).  PPD family members are part 
of the small RNA-mediated gene silencing machinery.    In small RNA-mediated gene silencing, 
small non-coding RNAs act as sequence specific silencers of target genes.  Short-interferring 
RNAs (siRNA) and microRNAs (miRNA) are processed from long primary transcripts via Dicer 
and then exert their gene silencing effects by forming a complex with a multi-protein (including 
Dicer) RNA-induced silencing complex (RISC).  The RISC always contains a member of the 
PPD family, usually of the Ago subfamily.  This complex interacts with specific mRNA targets to 






Interestingly neither Piwi, nor its two Drosophila homologues – Aubergine and Ago3 (the 
latter despite the nomenclature belonging to the Piwi subfamily) had been found to interact 
directly with either miRNAs or siRNAs despite the presence of a conserved Piwi domain 
common to both subfamilies, suggesting the presence of a third class of small RNAs.  In fact a 
detailed analysis of small RNAs in Drosophila during development did uncover a third group of 
small RNAs (24-29nt) [46] which are longer than either miRNA or siRNA., have a bias for a 
 
Figure 1.3 The PPD family is divided into the Ago and Piwi subfamilies 
The PPD family is divided into the Ago and Piwi subfamilies.  Hiwi is the human 







uridine at their 5' end and are 2’-O-methylated at their 3’end [47,48,49,50,51] . This novel class 
of small RNAs has been shown to be Dicer1 and Dicer 2 independent [52]. Since these small 
RNAs corresponded to genomic areas containing highly repetitive and transposon sequences 
[46], they were termed repeat associated small interfering RNAs - rasiRNAs. Subsequently, 
rasiRNAs in Drosophila germline cells were shown to associate specifically with Piwi and 
Aubergine and to be critical for silencing transposon elements [52]. Furthermore, endogenous 
Piwi immunopurified from Drosophila ovary was shown to exclusively associate with rasiRNAs 
[35]. rasiRNAs associating with Aubergine or Piwi corresponded to the antisense strand of 
retrotransposons, while Ago3-associated rasiRNAs were derived mainly from the sense strand. 
Follow up studies have recently identified rasiRNAs in Drosophila somatic cells as well [53].  
Due to their specific association with Piwis, rasiRNAs have been renamed as piwi-interacting, or 
piRNAs.  piRNAs have been identified in the germline of a variety of model organisms, including  
planarians[42,43], Drosophila [46], zebrafish [37], mice [54] and humans [54].   
Although siRNA and miRNA are thought to exert their gene silencing effects post-
transcriptionally, there is evidence that piRNAs/Piwis can exert their transposon silencing effects 
through either PTGS or through epigenetic/transcriptional mechanisms.   
Post-transcriptional transposon silencing via piRNAs and biogenesis of piRNAs 
A proposed post-transcriptional transposon silencing mechanism of piRNAs has been 
proposed in which long primary piRNA transcripts (derived from transposon regions) are 
alternately cleaved by Piwi-piRNA complexes to generate piRNAs and silence transposons.  
This is termed the ping-pong cycle (Figure 1.4, adapted from [3]).  
Since all three Drosophila Piwi homologues were shown to have endonuclease activity, a 
model was proposed in which the 5' end of piRNAs is determined and cleaved by AGO3-piRNA 





complexes through a similar piRNA-guided cleavage event [34]. In essence, in this ping-pong 
cycle of cleavage and alternate recognition of sense and antisense, primary piRNAs (believed to 
originate from long single-stranded precursors that correlate to transposon repeats) can be 
amplified if complementary transcripts are available. Amplification initiates when the 
endonucleolytic activity of Piwi proteins is used to cleave complementary transcripts which 
induces the formation of a new, secondary piRNA with its 5 ′ end precisely at the cleavage site. 
The secondary piRNA can in turn regenerate the initial piRNA by cleavage of its complementary 
target [36]. This “post-transcriptional gene silencing” mechanism of action suggests that 
transposon transcripts are cleaved to induce their silencing and generate piRNAs.   
The ping-pong cycle is thought to exist in mice as well.  Association of Piwi mouse 
homologues Miwi and Miwi2, was shown to be necessary for their cytoplasmic localization and 
participation in the ping-pong mechanism of piRNA biogenesis. Furthermore, Miwi2 was shown 
to assume the functional role of Piwi in the “ping-pong” cycle of piRNA biogenesis [3,55].  Finally 
all three Piwi homologue knockout mice exhibit defects in meiosis which may or may not be 
related to translational repression [54,55,56,57].  
Taken together, these data suggest that an alternate cleavage mechanism for piRNA 








Epigenetic/transcriptional transposon silencing via piRNAs 
 There is a growing body of evidence from a variety of model systems that suggests piRNA-
Piwi pathway components silence transposons in a chromatin-associated mechanism 
(epigenetic/transcriptional mechanism) in order to maintain genomic integrity.  piRNA-Piwi 
complexes are thought to ensure stem cell maintenance by inhibiting transposon migration 
[36,58] during early development via an indirect (since Hiwi has no known direct chromatin 
 
Figure 1.4 Ping-pong cycle of piRNA biogenesis 
Piwi homologs bind and catalyze cleavage of a long piRNA precursor and 
target transcript (referred to as a ping pong cycle) and induce target transcript 
cleavage in a post-transcriptional silencing mechanism.   Piwis/piRNAs are 







modifiying function) up-regulation of epigenetically based silencing machinery (i.e., DNA 
methylation) [55,59,60]. Specifically, previous studies have shown that transposon-specific 
DNA-methylation was reduced and transposon activity was elevated following silencing of Hiwi 
(or its orthologs). Although transposons promote evolutionary diversity in lower organisms, their 
unchecked migration in higher organisms can result in disruption of genomic integrity [61] and 
thus Piwi proteins may have developed as an evolutionary defense system for multi-cellular 
species.   
Piwi-associated piRNAs correspond to all types of genomic sequences [62]. One third of 
them correspond to unique sequences in the genome, including gene-coding sequences and 
intergenic sequences. The remaining two thirds are transcribed from repetitive sequences. In 
fact, most of the repetitive piRNAs are derived from transposon sequences that account for only 
about 10% of the fully assembled euchromatic genome. These piRNAs are especially 
overrepresented in retrotransposon encoding regions. Large numbers of Piwi-associated 
piRNAs are mapped into pericentromeric regions, subtelomeric regions, and telomeres. This 
broad distribution of piRNAs in nongene coding regions implicates their potential role in 
epigenetic regulation [62,63]. 
Even in mice where Piwi orthologs have been more extensively studied in terms of 
DNA methylation [55,59] the exact mechanism by which Piwi family members mediate 
DNA methylation during normal embryological development is still unclear. 
The role of Piwi in human cancers 
 Given the importance of Piwis in silencing transposon migration in order to maintain 
genome integrity, and given their exclusive stem cell expression, it is surprising that a number of 
reports find that Hiwi is aberrantly expressed in all cancers examined thus far.  Hiwi is highly 
expressed in diverse cancers, including seminomas [64], gliomas [65], squamous cell 





colleagues [26,27] finds that Hiwi is highly expressed primary soft tissue sarcomas, 
where higher Hiwi mRNA levels were predictive of worse clinical outcomes.  These data 
lead to an obvious conundrum: why would a gene that is critical for maintaining genome 
integrity during development be highly expressed in cancer? Since the above studies 
focused exclusively on Hiwi expression levels in cancer cells, mechanistic insight into 
Hiwi’s role in tumorigenesis remains completely unexamined. 
Piwi-interacting RNAs in non-human models 
A large focus of piRNA research has been dedicated to elucidating their role in germline 
stem cells.  piRNAs were isolated from rodent testes by 4 different groups simultaneously 
[54,56,57,70], suggesting that this novel class of small RNAs were specific to male germline 
stem cells.  Additionally, the zebrafish Piwi ortholog, Ziwi, is expressed exclusively in the gonad 
[71], further suggesting that the piRNA-Piwi pathway is specific to the germ-line.  Analysis of 
mouse oocytes revealed no small RNAs that correspond to piRNAs, further strengthening the 
assertion that piRNAs played a specific role in the male germline.   
   The questions of piRNA function in all tissues in which they have been identified remain 
open, although work from germline stem cells in both Drosophila and mouse models partially 
answer these questions.  Most piRNAs are not complementary to the mRNA of potential target 
genes (unlike miRNAs), further supporting the hypothesis that piRNAs are more likely to be 
involved in chromatin-associated regulation rather than post-transcriptional regulation [72].   
While many mechanistic details remain unclear, there is mounting evidence that piRNAs (and 
Piwi family proteins) mediate transposon silencing via chromatin-assocaited (epigenetic), rather 
than post-transcriptional mechanisms. 
Work in Drosophila implicates piRNAs in using epigenetic mechanisms to exert their 





[62]: piRNAs have been identified at heterochromatic regions and heterochromatin protein 1a 
(HP1a) was found to  bind to piRNA and Piwi.  This work implies that piRNA-Piwi pathway 
components may form a piRNA complex on chromatin that includes other chromatin modifying 
agents such as HP1a.  
Though mechanistic insights into the function of piRNAs in the germline are limited, work 
from mouse models of Miwi and Mili (mouse Piwi orthologs) deficiency find that expression of 
these Piwi orthologs is necessary for spermatogenesis [44,73]. Upon knock out of Mili or Miwi, 
transposon expression is activated [45].  Moreover, de novo methylation of IAP and Line1 
transposon region is reduced.   Additionally, Mili and Miwi null testes were sequenced to 
examine changes in piRNA populations.  Indeed, piRNAs were dramatically reduced upon Mili 
knock out, while the miRNA population remained unchanged.  These data implicate de novo 
methylation as an important chromatin-associated (epigenetic) mechanism of the piRNA-Piwi 
pathway to maintain transposon silencing. 
In a complementary study, loss of murine Piwi ortholog Miwi2 in germ stem cells results 
in increased transposon expression due to a loss of DNA methylation at transposon sites [59].   
This epigenetic methylation mark has been further implicated as a mechanism for piRNA-
mediated transposon silencing in order to maintain genome integrity:  Mili and Miwi2 are 
required for de novo methylation of transposons in the murine testis [45,55], thus showing their 
importance in establishing rather than maintaining DNA methylation patterns.  It is possible that 
piRNAs might play a role as guide for DNA methylation machinery to transposons.    Testes 
from mice mutant for DNMT3L, a DNA methyltransferase enzyme which regulates de novo 
methylation, still have a piRNA population.  This suggests that not only are Mili and Miwi2 
required for de novo methylation of transposon sites, but they also act upstream of DNMT3L 





post-transcriptional regulation—of transposon silencing in order to maintain genomic integrity of 
the germline. 
Interestingly, piRNAs identified in the male germline seem to fall into 2 categories: those 
that associate with Mili during early spermatogenesis, and those that associate with Miwi during 
late spermatogenesis [74].  Mili-associated piRNAs are typically 3-6 nucleotides shorter than 
those that associate with Miwi.  These data suggest that these 2 groups of piRNAs might play 
distinct roles in the germline, although more detailed aspects of these roles are still being 
investigated. 
Given the evidence that Piwis mediate transposon silencing via DNA methylation, it is 
reasonable to expect Piwi localization to the nucleus.  However, many groups have identified 
cytoplasmic expression of the human Piwi homolog, Hiwi [69,75,76].  This incongruity suggests 
that Piwis (and their corresponding piRNAs) might be shuttled into the nucleus in a carefully 
regulated manner. A recent review by Siomi and colleagues [77] suggest a model for Drosophila  
in which mature piRNAs complex with Piwis in the cytoplasm and this Piwi-piRNA complex is 
transported into the  nucleus to carry out its epigenetic silencing functions.  Because there is a 
high degree of homology of Piwis from different organisms, it’s likely that this model might be 
more widely applicable.  Alternatively, cytoplasmic Piwis might act through intermediary 
proteins, such as DNA methytransferases to exert their epigenetic silencing effects. 
The germline restriction of piRNAs has recently been called into question by a growing 
body of evidence examining piRNAs in various cell types.  piRNAs have been identified outside 
germ stem cells, for example, in somatic cells of the Drosophila ovary [78].  A recent study also 
found piRNAs in neurons of the mouse central nervous system [79].  The authors found that 
piRNA inhibition results in a decrease in dendritic spine formation, a key measure of synaptic 





various fly, mouse and macaque somatic tissues, including pancreas and cortex [80].  While 
these piRNA–like molecules were comparable to piRNAs in most criteria (length, distribution) 
and Piwi family proteins were identified in the examined tissues, a direct association of these 
small RNAs with Piwi family proteins was not shown.  Taken together, these data suggest that 
piRNA populations may exist in a variety of somatic tissues. A piRNA population has also been 
identified in HeLa cells [81], an cervical cancer-derived cell line. Although the piRNA population 
in HeLa cell is much smaller compared to that found in murine germline stem cells, it is still 
localized to the periphery of the nucleus, consistent with previous studies [82].   Moreover, Wu 
and colleagues recently identified a piRNA population in murine mesenchymal stem cells 
(MSCs) [83].  However, our studies (discussed in Chapters 3 and 4) suggest that piRNAs exist 
in our murine MSCs without any detectable Piwi homolog expression.  Together, these data 
suggest that, while piRNAs may be present in a variety of stem cell and somatic cell types, Piwi 
protein expression is much more limited, as it is found only in the germline during normal 
development. 
Piwi interacting RNAs in human cancer 
Since piRNA populations have been identified in a variety of germline and somatic 
tissues, much work has been undertaken to elucidate the role of small RNAs in cancer.  
miRNAs and their gene targets have been characterized in a variety of cancers, including breast 
[84], prostate [85] and liver [86] cancers.  However, piRNAs are understudied in cancers and 
until recently were thought to be entirely absent from cancer cells.  Determining the roles of 
piRNAs in cancers is becoming increasingly important to fully understand the cellular changes 
that occur during cancer.   
While Piwi family members are normally expressed in germline stem cells, their 





adult tissue stem cells do not express Hiwi. A growing number studies have found human Piwi 
homologs Hiwi and Hili to be aberrantly over-expressed in a variety of  human cancers 
[65,66,67,69,87], including cancers originating from the germline (testicular seminomas [64]) 
and those originating from MSCs (sarcomas [26]). These reports suggest that in a tumorigenic 
state, a cell’s piRNA-Piwi pathway components might be altered.  
piRNAs have not been thoroughly studied in cancers, however a few preliminary studies 
suggest that piRNAs are altered in cancers. A specific piRNA, piRNA 651, has been shown to 
be aberrantly over-expressed in multiple cancers, including gastric, colon, lung and breast 
cancer tissues, when compared with normal tissues [88].  Furthermore, inhibition of this piRNA 
in gastric cancer cell lines (another cancer in which Hiwi is over-expressed [69]) decreased 
cellular growth.  While the growth inhibition effect of the piRNA antagonist was modest, these 
data are suggestive of an important potential role for aberrant piRNA expression in contributing 
to over-proliferation in cancer cells.   
piRNAs were further investigated in gastric cancer by their detection in peripheral blood 
from patients [89].    Two specific piRNAs, one of which was piRNA 651, were chosen for 
evaluation and both were significantly lower in peripheral blood from gastric cancer patients, 
compared to healthy controls. This report suggests that piRNA detection might be a valid 
biomarker for identifying circulating gastric cancer cells in the blood.  While these data may 
seem contradictory to the Liu, et al, report which finds high piRNA 651  levels in cancer tissues 
[69], it is important to note that these are the first studies to examine piRNA expression levels in 
cancer and much more investigation is necessary, both to validate these studies and to identify 
piRNA expression in additional cancer types.  Importantly, these studies did not provide 
evidence for a general alteration of the piRNA population in cancer versus normal cells; rather 





piRNA population.  Because no evidence was given for the rationale behind evaluating these 2 
specific piRNAs, the potential alterations in all other piRNAs remain unknown.  Knowing how 
those 2 piRNAs were chosen for further analysis would provide valuable information on the 
piRNA populations in these cancers, but also on the application of this work to other cancers 
which have high levels of Hiwi. Further, because no mechanistic insight into the role of piRNAs 
in cancer has been explored, it is not known if piRNAs might be driving tumorigenesis or if their 
alteration is merely a bystander effect that is part of the cell’s stem cell recapitulation process.   
While Piwi orthologs have been found to be highly expressed in a variety of cancer types, the 
presence or absence of piRNAs in a variety of cancers has not been fully explored.   
On one hand, Hiwi and its orthologs are critical for maintenance of germline stem 
cells during normal development.  On the other hand, Hiwi aberrant expression has been 
identified in all cancers examined, including in sarcomas.  A potential connection 
between MSCs, sarcomas, and Hiwi remains unexplored and the role of Hiwi in sarcomas 
is still unclear.   How Hiwi may act appropriately to promote genomic integrity during 
early development (via transposon silencing) and inappropriately in adult tissues with 







2. Chapter 2: A novel oncogenic role for Hiwi 
Hiwi in Sarcomas 
Recent studies by Taubert and colleagues [26,27] identified Hiwi mRNA levels to be 
upregulated in primary soft tissue sarcoma samples.  These data were intriguing for a variety of 
reasons.  As a stem cell maintenance gene expressed during normal development, Piwis are 
not expected to be expressed in the adult organism.  Moreover, Hiwi was previously identified 
only in human hematopoietic progenitor cells [28].  Thirdly, this was the first report of Hiwi 
expression in sarcomas, although work from others had shown that Hiwi is elevated in gastric 
cancer [69].   
Rationale of the Study 
 As described earlier, Hiwi mRNA has been detected at very high levels in primary 
sarcomas, using a quantitative PCR technique [26].  Moreover, high levels of Hiwi mRNA 
expression were correlated with a poorer clinical outcome for the patient.  We wanted to further 
explore a possible connection between sarcomas and Hiwi, including a functional role for Hiwi in 
an aberrant cancer state.  Before the completion of our studies, the role of Hiwi in cancer 
generally, and in sarcomas specifically, remained unexplored areas of cancer/stem cell biology.    
Experimental Design 
 In order to elucidate a functional connection between Hiwi and sarcomas, we first 
characterized Hiwi expression at the protein level in primary human sarcoma samples.  We then 
generated both Hiwi over-expression and Hiwi knock down models in vitro.  Because previous 
work from our lab implicates mesenchymal stem cells as the likely call of origin for sarcomas 
[1,9,10], we generated a Hiwi over-expression model in mesenchymal stem cells and evaluated 





generated a conditional knock-down model of Hiwi in a sarcoma cell line, MFH, which 
expresses Hiwi protein at a very high level.  Lastly, we generated a mesoderm-specific 
transgenic mouse model of Hiwi over-expression in order to determine Hiwi’s role in 
sarcomagenesis in vivo. 
Results 
1. Hiwi is highly expressed in human primary undifferentiated sarcomas 
Following previous PCR-based observations that Hiwi is expressed in sarcomas [27] and 
that its expression correlates with prognosis [26], we examined Hiwi protein levels via 
immunohistochemistry (IHC) in a large primary human sarcoma tissue microarray (TMA) 
composed of numerous soft-tissue sarcomas (previously described by us [9]). The sarcoma 
TMA contains 12 leiyomyosarcoma cases, 10 high grade undifferentiated sarcoma cases, 10 
well-differentiated sarcoma cases, 3 pleiomorphic sarcoma cases, 12 dedifferentiated sarcoma 
cases,  6 low grade myxoid sarcoma cases, and 6 high grade myxoid sarcoma cases.  Each 
case was present in triplicate.  The indicated sarcoma subtypes were scored from 0 to 2 blindly 
by sarcoma pathologists. To examine the relationship between cellular differentiation and tumor 
grade, we focused on a panel of liposarcomas, since we have previously shown that high grade 
undifferentiated sarcomas (HGUS), dedifferentiated liposarcomas, pleomorphic liposarcomas, 
and well-differentiated lipoarcomas correspond to a gradual adipocytic differentiation spectrum 
[10]).  We noted that Hiwi levels correlated directly with grade and indirectly with tumor cellular 
differentiation.  (Figure 2.1A). Overall Hiwi is expressed at significantly higher levels (p<0.005) 
in undifferentiated sarcoma subtypes compared with more well-differentiated subtypes (Figure 
2.1B).  Both tumor grade and tumor cellular differentiation have been shown to correlate with 





undifferentiated mesenchymal tumorigenic state and thus by definition designates a poor 
prognostic outcome [90].  
  
2. Hiwi is not chromosomally amplified in Hiwi-expressing sarcomas 
We then assayed, via DNA fluorescence in situ hybridization (DNA FISH), for Hiwi 
chromosomal amplification using the same sarcoma TMA used to validate Hiwi protein levels 
and correlated Hiwi IHC-based expression to Hiwi chromosomal amplification. Only one case 
 
Figure 2.1 Hiwi is highly expressed in human undifferentiated sarcoma samples 
(A) Immunohistochemical (IHC) analysis of Hiwi on a human sarcoma tissue microarray 
(TMA). Ten cases of each subtype (present in triplicate) were scored from 0 to2 blindly by 
sarcoma pathologists. Representative pictures are shown.  (B) Average scores are plotted 
here for each subtype. Error bars represent standard error ** = p< 0.005 by Student’s T-






out of 45 examined carried a true chromosomal amplification of the Hiwi locus on chromosomal 
12 (Figure 2.2). We have assayed for Hiwi amplification using the tissue microarray (Figure 
2.1A) and attempted to correlate IHC-based expression to Hiwi amplification.  However only one 
case out of 45 examined carried a true chromosomal amplification of the Hiwi locus on 
chromosome 12 (Figure 2.2A), a few cases (5 out of 45) had a copy number increase of 
chromosome 12 (Figure 2.2B) while the majority of cases (39 out of 45), including all HGUS 
cases, did not have any amplification of chromosome 12 (Figure 2.2C).  These data suggest 
that although Hiwi is expressed at high levels in the most undifferentiated sarcoma subtypes, 






3. Generation of Hiwi over-expressing mesenchymal stem cells 
To assess whether Hiwi merely associates with inhibition of differentiation and 
tumorigenesis, or whether Hiwi may directly inhibit differentiation and promote sarcomagenesis, 
we expressed Hiwi in sarcoma precursors (i.e., mesenchymal stem cells) using a lentiviral 
construct.  In order to validate our Hiwi-MSCs beyond IHC staining, we performed a quantitative 
RT-PCR (Figure 2.3A) on parental MSCs, MSC5 (a non Hiwi-expressing clone), and Hiwi-
 
Figure 2.2 Hiwi is not chromosomally amplified in Hiwi-expressing sarcomas 
DNA FISH was performed on the human sarcoma TMA, using a probe against the Hiwi 
locus on chromosome 12.  (A) Analysis of the sarcomas reveals only 1 out of 45 cases 
that has a true amplification of Hiwi, a dedifferentiated liposarcoma.  (B) A few cases (5 
out of 45) have a copy number increase of Hiwi.  (C)  However, the majority of cases (39 
out of 45), including all HGUS Hiwi-expressing cases, have no chromosomal 






MSCs 3 and 7 (Hiwi-expressing clones), along with their corresponding no reverse transcriptase 
controls.  Hiwi-MSC 3 and 7 express high levels of Hiwi, as compared to parental MSCs and 
MSC5.  Additionally, we performed western blotting analysis of various clones (Figure 2.3B) 
obtained during the transfection/infection procedure.  MSC2, 5 and 6, along with parental MSCs, 
showed no Hiwi expression.  Hiwi-MSC clones 3 and 7 express Hiwi (middle band; 100kDa).  
AGS and N87 gastric cancer cell lines have been previously reported [69] to express Hiwi and 
were used as positive controls.  However, Hiwi is more readily detected in N87 at this exposure, 
and both are expressed at much lower levels compared to either of our Hiwi-expressing clones 
(Hiwi-MSC 3 and 7).  The Hiwi band for N87 control cells may be slightly higher than the MSC-
Hiwi 7 Hiwi band, likely due to technical difficulties with this antibody.  This is consistently seen 
in our western blots using this antibody to detect N87 and clonal Hiwi expression.  Because 
commercially available antibodies for Hiwi are more suited for IHC rather than western blotting, 
the western blot shown in Figure 2.3B shows non-specific banding and IHC is preferentially 
used in the following studies. A high non-specific band at about 115kDa is consistently seen in 
our Western blots with this antibody.  Additionally, a lower band around 82kDa is seen in the 
Hiwi-expressing clones (Hiwi-MSC 3 and 7).  This band may represent a degradation product of 






4. Hiwi over-expression blocks mesenchymal differentiation capacity in vitro  
We first observed that Hiwi-expressing MSCs show a distinct morphology when grown in 
culture.  Compared to parental MSCs which grow in a monolayer, the Hiwi-expressing MSCs 
grow in a clumped manner where colonies form and cells begin to grow on top of each other 
 
Figure 2.3 Generation of Hiwi-expressing mesenchymal stem cells 
(A) Parental MSCs, MSC5 (a clone which is selection-marker resistant but doesn’t 
express Hiwi), and Hiwi–expressing clones 3 and 7 were analyzed by quantitative RT-
PCR for Hiwi expression.  MSC-Hiwi 7 was arbitrarily set at 1.  (B) MSC clones were 
analyzed by Western Blot for Hiwi expression levels.  MSC-Hiwi 3 and 7 were positive 
clones, where as MSC2, 5, and 6 gained selection marker resistance without expressing 
Hiwi.  MSC5 was chosen for further experiments.  AGS and N87 gastric cancer cell lines 
have been previously reported as positive controls for Hiwi expression. A high non-
specific band at about 115kDa is consistently seen in our Western blots with this 
antibody.  Additionally, a lower band around 82kDa is seen in the Hiwi-expressing clones 
(Hiwi-MSC 3 and 7).  This band may represent a degradation product of Hiwi, however 





(top row, Figure 2.4).  To assess whether Hiwi merely associates with inhibition of 
differentiation and tumorigenesis, or whether Hiwi may directly inhibit differentiation, we 
expressed Hiwi in sarcoma precursors (i.e., mesenchymal stem cells, Figure 2.3). Hiwi-
expressing MSCs (Hiwi-MSC 3 and 7) and parental MSCs were cultured in either adipogenic or 
osteogenic differentiation medium [9] and, as per standards of the field, were assayed for 
phenotypic maturation with either Alizarin-Red-S for bone/calcium mineralization or with Oil-
Red-O for fat accumulation. Hiwi-expressing MSCs (Hiwi-MSC-3&7; columns 2 and 3, Figure 
2.4) show impaired differentiation into both osteogenic (second row, Figure 2.4) and adipogenic 
(third row, Figure 2.4) mesenchymal lineages as compared to parental MSCs (pMSC; column 
1, Figure 2.4), which readily accumulate mineralized calcium and form adipocytic foci.  Calcium 
matrix formation, as measured by Alizarin-red-S staining, is significantly decreased in Hiwi-
MSCs compared to parental MSCs.  Similarly, lipid formation, as measured by Oil-Red-O 
staining decreased in Hiwi MSCs compared to 25% parental MSCs. These data suggest that 
Hiwi expression blocks the capacity of MSCs to differentiate down typical mesenchymal 






5. Hiwi over-expression transforms mesenchymal stem cells in vivo 
In order to further characterize the effects of Hiwi over-expression in MSCs, we asked 
whether Hiwi may transform these sarcoma precursor cells to become tumorigenic.  To test this 
hypothesis, we inoculated Hiwi-expressing MSCs (Hiwi-MSC 3 and 7), parental MSCs and a 
non-expressing, antibiotic resistant MSC clone (MSC5; isolated from our initial transduction) into 
NOD-SCID-Gamma mice. Tumors formed from MSC-Hiwi 3 and 7 inoculations after five weeks. 
Morphological analysis (Fabrizio Remotti MD, Department of Pathology, CUMC) showed that 
 
Figure 2.4 Hiwi over-expression blocks mesenchymal differentiation in vitro 
Top row: IHC analysis reveals Hiwi-MSC clones (3 and 7) have a distinct clumped 
morphology and highly express Hiwi. Middle row: Day 21 in osteogenic media.  Calcium 
matrix formation measured by Alizarin Red S stain is decreased in Hiwi-MSCs, 
compared to pMSC. Bottom row: Day 21 in adipogenic media. Lipid formation 
measured by Oil Red O stain is decreased in Hiwi-MSCs compared to pMSC. 





tumors derived from Hiwi-MSC 3 and 7 inoculations were high grade sarcomas. Further IHC 
analysis also showed that they expressed Hiwi (Figure 2.5A, bottom row). In contrast to MSC-
Hiwi 3 and 7, parental MSCs and MSC5 formed small fibrous plaques devoid of tumor cells 
(Figure 2.5A, middle row,). Xenograft weights were quantified (Figure 2.5B) and xenografts 
derived from Hiwi-MSCs were significantly larger than small calcified nodules found in parental 
MSCs and in a non-Hiwi expressing clone, MSC5.  Taken together, these data suggest that Hiwi 






6. Stem cells are more sensitive to Hiwi-mediated transformation 
To further explore the oncogenic properties of Hiwi we performed classical oncogene 
cooperation assays in which Hiwi was infected into MSCs and Mouse Embryonic Fibroblasts 
(MEFs) alone and in conjunction with Ras. Hiwi-transformed MSCs form large colonies (p<0.05, 
compared to untransfected controls), which significantly increase in size and frequency when 
 
Figure 2.5 Hiwi transforms MSC to become tumorigenic in vivo 
(A) Top row: Xenograft tumors derived from Hiwi-MSCs. Middle row: H&E analysis 
reveals tumors from Hiwi-MSCs are undifferentiated sarcomas.  Bottom row: By IHC 
analysis, tumors from Hiwi-MSCs continue to express Hiwi. All experiments were 
performed in 3 mice (n=3). Each mouse was injected with the 2 Hiwi-negative MSCs 
at the top and bottom of the left flank, and the 2 Hiwi-positive MSCs at the top and 
bottom of the right flank. (B) Quantification of average xenograft size in grams. Error 
bars represent standard error and weights are the average of 3 tumors (1 per mouse).   







combined with Ras (p<0.005) (Figure 2.6).  Interestingly we did not observe a similar 
transformative effect using MEFs suggesting that Hiwi's oncogenic function may depend on the 
context of cell type. These results indicate that Hiwi is sufficient to transform progenitor cells into 
sarcomas. Taken together our data suggest that stem cells may be more sensitive to Hiwi-
mediated transformation, compared to more differentiated cell types.  We are aware that certain 
control experiments must be completed in order to definitively show that progenitor cells are 
differentially sensitive to transformation via Hiwi, including measuring transfection efficiency and 
transgene expression levels.  However, these are preliminary data which are promising and we 
are continuing to pursue this line of investigation.   Although our data are intriguing, we 
acknowledge that further studies must be done to establish the sensitivity of stem cell 
specifically to Hiwi-mediated transformation.  This might include similar colony forming assays 






7. A mesoderm-specific transgenic mouse model of Hiwi develops lipomatous lesions 
We further generated transgenic mice expressing Hiwi under the control of the early 
mesodermally restricted Prx1 enhancer element [91]. The Prx1 enhancer element drives the 
expression of genes in the developing limb bud mesoderm, but not ectoderm.  51 Prx1-Hiwi 
expressing progeny have been generated to date. Early sarcoma formation was identified in two 
(4%) of 51 Prx1-Hiwi mice at 12 weeks, in a known Prx1 distribution (on the limbs), that contain 
both well-differentiated and high grade components and express Hiwi (Figure 2.7). No other 
developmental or pathological abnormalities were observed in these Prx-Hiwi transgenic mice.  
No sarcoma formation was found in wildtype, Hiwi-non-expressing littermate control mice.  
 
Figure 2.6 Stem cells are more sensitive to Hiwi-mediated transformation 
(A) MEFs (left column) or MSCs (right column) were transfected with either Hiwi alone, Ras 
alone or with both Hiwi and Ras and then put into colony formation assays.  At 4 weeks in 
colony formation assay, both Hiwi alone and Ras alone formed colonies in MSCs (p<0.05 
compared to untransfected control) and together they formed significantly more colonies 
(p<0.005 compared to untransfected control).  No significant changes in colony formation 
were observed in the transfected MEFs (p>0.5 for all transfections compared to 
untransfected control).  All experiments were performed in triplicate.  Representative 
pictures are shown here all at 20X magnification. (B) Quantification of number of colonies 
formed during the experiment described in (A).  Experiment was repeated in quadruplicate 






Although we realize this is a low tumor incidence, it is still higher than  the tumor incidence rate 
found in mice bearing the deletion of the retinoblastoma tumor suppressor under the same 
promoter (which is no tumor formation at all) [92]; suggesting to us that the low incidence rate 
may under-represent Hiwi's tumorigenic potential in this model.  The organs of Prx-Hiwi-
expressing mice, both those that form tumors and those that do not, show no discernible 
abnormalities by H&E (reviewed by pathologists Drs. Mireia Castillo-Martin and Fabrizio 
Remotti).  There was no evidence of a pre-neoplastic state in Prx-Hiwi mice which do not form 
tumors, based on gross dissection and H&E review.  While these mice have not been further 
characterized, we are working on generating the next iteration of the Hiwi transgenic mouse 
model, described in detail in chapter 5. 
  
8. Generation of short-hairpin Hiwi knock down sarcoma cells 
Having shown that Hiwi expression in sarcoma precursors leads to sarcomagenesis, we 
then asked if Hiwi is necessary for maintenance of the sarcoma phenotype. We have previously 
 
Figure 2.7 Mesoderm-specific transgenic mouse model of Hiwi over-expression 
Transgenic mouse model of Hiwi forms sarcomas (left panel) with both well-differentiated 
and poorly-differentiated sections (H&E panel) and continues to express Hiwi (right 







characterized a panel of human sarcoma cell lines [93]. Previously reported gene expression 
analysis predicted that the high grade undifferentiated sarcoma cell line, MFH, expressed high 
levels of Hiwi at the RNA level.  We validated the undifferentiated sarcoma cell line, MFH 
(previously characterized by us [9,93], endogenously expresses Hiwi mRNA at very high levels 
via quantitative RT-PCR (Figure 2.8A).  We then assessed Hiwi protein expression via IHC in 
MFH cells as compared to other sarcoma cell lines (Figure 2.8B). Both RT-PCR and IHC 
confirm our initial gene expression analysis and identify MFH as a sarcoma cell line that 
endogenously expresses Hiwi. 
We then engineered MFH cells to express doxycycline-inducible Hiwi-short hairpin; (dox-ind-
sh-Hiwi MFH; Figure 2.8C, top left panel). Both parental MFH cells and sh-scramble MFH 
negative control cells continue to express high levels of Hiwi. In contrast, doxycycline-treated 
sh-Hiwi MFH cells have dramatically reduced Hiwi levels (Figure 2.8; Clones C and E were 
chosen for further analyses). We recognize that knock-down data are often shown by western 
blotting, and here we use IHC to verify Hiwi knock-down.  IHC analysis was chosen over 






9. Short-hairpin Hiwi knock down re-establishes differentiation capacity and reduces 
colony formation capacity 
We then asked what the effect of Hiwi down-regulation might be on the capacity of MFH 
sarcoma cells to differentiate down a typical mesenchymal lineage. Although MFH cells do not 
undergo induced mesenchymal differentiation [9,93], dox-ind-sh-Hiwi MFH cells are able to 
undergo mesenchymal differentiation following doxycycline treatment and exposure to 
differentiation medium (Figure 2.9A).  Here, osteogenic differentiation is shown with the Alizarin 
Red S stain, as previously described. In contrast, in the absence of doxycycline (parental MFH 
 
Figure 2.8 Generation of short-hairpin Hiwi knock down sarcoma cells 
(A) Quantitative RT-PCR of Hiwi mRNA in a panel of human sarcoma cell lines.  (B) 
Immunohistochemical analysis of Hiwi protein in a panel of human sarcoma cell lines 
(C) Verification of inducible sh-Hiwi MFH clones by immunohistochemistry. sh-Hiwi 





cells) rapidly overgrow and die (as previously described [9,94]), presumably because they do 




Figure 2.9 Hiwi knock down re-establishes differentiation and reduces colony 
formation of sarcoma cells 
(A) Day 21 in osteogenic media.  Calcium matrix formation (measured by Alizarin Red 
S stain) is restored in sh-Hiwi MFH clones C and E (approximately 50% of cells 
staining), induced with doxycycline 7 days before addition of differentiation media and 
continued in doxycycline-spiked media during differentiation. (B) Doxycycline-induced 
sh-Hiwi MFH cells at 4 weeks in colony forming assay show decreased colony 
formation, as compared to uninduced sh-Hiwi MFH cells. p<0.001 for clone C and 
p<0.005 for clone E by Student’s T Test.  Representative pictures shown at 20X 
magnification (C) Quantification of colonies shown as fold change.  Experiment was 






We then further characterized these Hiwi knock down MFH cells by examining their colony 
forming capacity.  In vitro colony formation is a commonly used proxy for the tumorigenic 
potential of a given cell line.  Colony formation is significantly reduced to about 40% of untreated 
control for dox-ind-sh-Hiwi MFH clone C and to about 15% of untreated control for dox-ind-sh-
Hiwi MFH clone E (p<0.001 for clone C and p<0.005 for clone E; Figure 2.9B, quantified in 
Figure 2.9C).   
Discussion 
Using mesenchymal stem cells, transgenic mouse models and human tumor samples 
we show through this set of studies that Hiwi is directly tumorigenic, revealing a novel oncogenic 
role for Hiwi as a driver of tumorigenesis.  We have identified increased Hiwi protein expression 
in undifferentiated human sarcomas, though a direct genetic basis for this up-regulation of Hiwi 
in sarcomas is still lacking.  We found no characteristic chromosomal amplification of Hiwi in 
Hiwi-expressing human sarcomas.  Moreover, we have generated in vitro Hiwi over-expression 
and Hiwi knock down models which indicate that Hiwi expression blocks mesenchymal 
differentiation capacity and transforms cells to become tumorigenic.  Finally, an appendicular, 
mesoderm-specific transgenic mouse model of Hiwi shows that Hiwi over-expression forms 
sarcomas in vivo, albeit at a low rate of tumor incidence.   
To date, Hiwi has been found to be highly expressed in a variety of human cancers, 
including gastric [69], gliomas [65], pancreatic [67] and squamous cell carcinomas [66].  The 
majority of reports which identify increased Hiwi expression in cancer focus predominantly on its 
clinical significance.  For example, in sarcomas [26], hepatocellular carcinomas [95], and in 
colorectal cancer [96], Hiwi expression is an indicator of poor patient prognosis.  Because the 
focus of previously published studies was the role of Hiwi as a prognostic factor for various 





elevated secondarily in response to another driver of the tumorigenesis was not asked.  None of 
previously published studies have focused on the investigation of a potential oncogenic role for 
Hiwi in driving tumor formation and/or maintenance.  Our studies are the first to prove Hiwi can 
be a driver of sarcomagenesis and that sarcomas may be addicted to Hiwi expression for the 
maintenance of the tumor phenotype.   This novel oncogenic role for Hiwi shows that, while it 
may also be an important prognostic factor, Hiwi may be a viable therapeutic target. 
Throughout our short hairpin Hiwi knockdown studies in MFH sarcoma cells, we employ 
the commonly used technique of colony formation assays as an in vitro proxy for tumorigenic 
growth.  Since xenograft experiments were used for exploring the tumorigenicity Hiwi over-
expressing MSCs, we also attempted an analogous xenograft approach for our doxycycline-
inducible sh-Hiwi MFH model.  In vivo treatment of doxycycline to achieve continuous 
doxycycline-inducible gene expression changes in xenograft systems has been established [97].  
We attempted a similar experiment, in which sh-Hiwi MFH cells were induced in vitro with 
doxycycline, then subcutaneously injected into SCID mice.  To maintain knock down of Hiwi in 
vivo, the inoculated mice were given doxycycline water over the course of the experiment and 
tumor formation was monitored.  We found no significant changes in tumorigenic growth of the 
subcutaneously injected dox-sh-Hiwi MFH cells, as compared to control sh-Hiwi MFH cells 
which were never induced with doxycycline (Figure 2.10A).  Additionally, IHC staining for Hiwi 
in these xenografts shows no change in Hiwi expression during doxycycline induction in vivo 
(Figure 2.10B).    Because our colony forming assay results directly oppose these in vivo data, 
we venture that perhaps the doxycycline in the drinking water is not reaching the inoculation 
sites. This might be due to a lack of xenograft vascularization soon after inoculation, preventing 
doxycycline from maintaining Hiwi knockdown.  Once there is sufficient tumor vascularization, 
and doxycycline is able to reach the site, the tumorigenic growth has already occurred and 





parsing out the best method for doxycline delivery, we focused instead on more reliable and 
consistent in vitro colony formation assays during doxycline-induced Hiwi knock down, in which 
continuous Hiwi knock down is much more straightforward to ensure.  Colony formation assays 
have previously been reported to measure the tumorigenic growth of cancer cells [98,99] and 
their set up contains doxycycline for continuous Hiwi knock down.  Other commonly used in vitro 
assays for aspects of tumorigenicity are proliferation and invasion assays.  However, our 
decision to use colony formation assays reflects the fact that colony formation assays already 
include aspects of cellular proliferation and invasion.  Moreover, they are quantitative, providing 






Ours is also the first transgenic mouse model of Hiwi-mediated sarcoma formation.  
Xenograft assays of Hiwi over-expressing MSCs suggest that Hiwi drives tumor formation.  
Based on these data, we generated a mouse model of Hiwi over-expression under control of the 
Prx1 promoter [91].  While the tumor incidence rate of these Prx-Hiwi mice is less than 10%, it is 
still higher than that of transgenic mice in which the Retinoblastoma (Rb1) tumor suppressor 
gene is deleted under the same Prx1 promoter.  These Rb1 data lead us to believe that the Prx-
Hiwi transgenic mouse model does not fully recapitulate the tumorigenic potential of Hiwi.  It is 
 
Figure 2.10 sh-Hiwi MFH xenograft weights 
(A) Doxycycline induction in vivo does not affect sh-Hiwi MFH xenograft growth, likely due 
to difficulty in doxycycline arriving to the inoculation site to maintain Hiwi knockdown.  For 
simplicity, only clone C shown, although similar results were obtained from all clones 
tested. Error bars represent standard error and xenografts were performed in duplicate. 
(B)Representative pictures of xenografts derived from clone C stained for Hiwi.  All 





possible that Hiwi expression levels are simply too low under the Prx1 promoter to induce 
massive, widespread tumorigenic growth.  To this end, we have begun work on a transgenic 
mouse model of Hiwi expression under a pROSA-driven floxed stop which is crossed with Prx1-
Cre mice to induce Hiwi expression in Prx1 tissues (limb bud mesoderm), only after Cre 
recombination.  Another possibility for the low tumor incidence rate of the Prx1-Hiwi mouse 
model is that Hiwi over-expression alone is sufficient to establish tumors at a very low rate, but 
that Hiwi over-expression in a tumor-sensitive background leads to higher rates of tumor 
formation.  Hiwi might be more robustly oncogenic when there is a concurrent loss of Rb or Pten 
tumor suppressor genes.  To test this, we have begun crossing Prx1-Hiwi mice with those that 
have a Prx1-specific loss of either Rb or Pten tumor suppressors.  This is further discussed in 
Chapter 5.   
Though increased expression has been described in a variety of human cancers, the 
exact role of Hiwi in adult neoplastic tissues had not been explored.   Taken together, the 
studies described here are the first report of a novel oncogenic role for Hiwi as a driver of 
sarcomagenesis.  Using in vitro cell line models, a transgenic mouse model and human primary 
sarcoma samples, we show that Hiwi is highly expressed in primary sarcomas and that Hiwi 
expression results in both a differentiation block down typical mesenchymal lineages and 






Materials and Methods  
Colony Formation Assays 
Cells were suspended in 0.3% agar (Sigma) in culture medium and plated into 6 well plates, 
with a base layer of 0.6% agar in culture medium. For doxycyline and 5-azacytidine treatments, 
cells were pre-treated for 7 days in culture before beginning colony formation assay.  Cells were 
kept in drug-spiked media during the assay and monitored for colony formation.  Pictures were 
taken after 4 weeks.  Experiments were performed in 2 times, each time in duplicate. 
 
Immunohistochemistry (IHC) 
IHC was performed as previously described by us [93]. Briefly, formalin-fixed, paraffin-
embedded (FFPE) tissues were rehydrated and treated with citric buffer for antigen retrieval.  
Slides were blocked with 10% horse of goat serum in 2% BSA-PBS and then incubated in 
primary antibody (diluted in 2% BSA-PBS) overnight at 4°C. Following 30 minutes of secondary 
antibody and tertiary antibody (Vector Labs) incubation, slides were developed with 3,3-
Diaminobenzidine (DAB) and counterstained with Hematoxyalin. For cells, fixation was 
performed with 50% Methanol/Acetone for 10 minutes, then blocking, primary antibody 
incubation, and detection was performed as for FFPE IHC. Primary antibody used in these 
studies:  Hiwi (Abcam, 12337) 
 
Sarcoma Tissue Microarray (TMA) 
The TMA contained 10 cases of each sarcoma subtype in triplicate.  For TMA analysis, IHC 
staining was scored on a scale of 0 to 2 by multiple sarcoma pathologists.  The average score 







Standard western blotting technique was used.  Briefly, protein lysate was collected from cells 
with RIPA buffer (Boston BioProducts) and 50ug were run on a 4-20% Tris-glycine gradient gel 
(Invitrogen).  Nitrocellulose membranes were incubated overnight at 4°C in primary antibody: 
Hiwi (1:500 ProSci 45-735P). 
 
Bone and Fat Differentiation 
Bone or fat differentiation was assessed in MSCs after 21 days in bone or fat differentiation 
media, as previously published [9].  Approximate percentage of differentiated cells was 




NOD-SCID mice were subcutaneously injected, in triplicate, with 1 million cells of each indicated 
cell type, as described previously [93].  Tumor formation was monitored for 5 weeks and mice 
were sacrificed when tumor size reached 1cm, in accordance with Columbia University Animal 
Welfare and IUCAC policy under IRB protocol AAAA9669.   
 
Quantitative RT-PCR 
RNA was collected using Qiagen RNeasy kit.  Complimentary DNA (cDNA) was made from 1ug 
of RNA, according to instructions in the SuperScript III cDNA synthesis kit (Invitrogen). 1uL of 
cDNA was used in Qiagen QuantiTect Sybr mix, according tom manufacturer’s instructions.  
Samples were run on Stratagene MX3005p using the following cycling: 95 x 15m: 1 cycle /94 x 





sequence: F: CCCCAAGTCAGTGTGTGGTG, R: TATGCAGCGTGAGAACCAGC.  Normalizing 
Actin primers: F: AAACTGGAACGGTGAAGGTG, R: GTGGCTTTTAGGATGGCAAG 
 
DNA Fluorescence In Situ Hybridization (DNA FISH) 
DNA FISH was performed by Dr. Murty and colleagues at the CUMC Cytogenetics Core Facility.  
A probe against the Hiwi locus on chromosome 12 was designed and used to identify 
chromosomal amplification of samples present on the sarcoma TMA.   
 






3. Chapter 3: Identification of piwi-interacting RNAs (piRNAs) in 
mesenchymal stem cells 
piRNAs are present in germline and somatic cells 
A novel class of small RNAs, called piwi-interacting RNAs (piRNAs), maintains genome 
integrity by epigenetically silencing transposons via DNA methylation, especially in germline 
stem cells. piRNAs are thought to interact exclusively with the Piwi family of proteins.   
A large focus of piRNA research has been dedicated to elucidating their role in germline 
stem cells.  piRNAs were isolated from rodent testes by 4 different groups simultaneously 
[54,56,57,70], suggesting that this novel class of small RNAs were specific to male germline 
stem cells.  Additionally, the zebrafish Piwi homolog, Ziwi, is expressed exclusively in the gonad 
[71], further suggesting that the piRNA pathway is specific to the germline.   
The germline restriction of piRNAs has recently been called into question by a growing 
body of evidence examining piRNAs in various cell types.  piRNAs have been identified outside 
germ stem cells, for example, in somatic cells of the Drosophila ovary [78].  A recent study also 
found piRNAs in neurons of the mouse central nervous system [79].  The authors found that 
piRNA inhibition results in a decrease in dendritic spine formation, a key measure of synaptic 
function.  Recent work identified piRNA-like molecules in various fly, mouse and macaque 
somatic tissues, including pancreas and cortex [80].  It is important to note that while these 
piRNA–like molecules were comparable to piRNAs in most relevant criteria (length, distribution) 
and Piwi family proteins were identified in the examined tissues, a direct association of these 
small RNAs with Piwi family proteins was not shown.  Taken together, these data suggest that 





A piRNA population has also been identified in HeLa cells [81], a cervical cancer-derived 
cell line. Although the piRNA population in HeLa cell is much smaller compared to that found in 
murine germline stem cells, it is still localized to the periphery of the nucleus, consistent with 
previous studies [82].   Moreover, Wu and colleagues recently identified a piRNA population in 
murine mesenchymal stem cells (MSCs) [83].  These piRNAs associate with Mili in the 
cytoplasm of MSCs and are thought to be important for keeping cellular proliferation in check.  
Importantly, Mili expression was examined by immunoprecipitation and western blot using the 
same Mili antibody, suggesting that actual Mili expression is much lower than the enriched band 
shown. There was no evidence that other murine Piwi orthologs are present in MSCs.   
Additionally we have shown that Mili, Miwi and Miwi2 (all 3 murine Piwi orthologs) are not 
readily detectable by RT-PCR from murine MSCs (Figure 3.1).  Together, these data suggest 
that, while piRNAs may be present in a variety of stem cell and somatic cell types, Piwi protein 






piRNAs are known to associate  exclusively with Piwi proteins.  Moreover, piRNAs rely 
on Piwi homologs for their biogenesis, via an alternate cleavage mechanism called the ping-
pong cycle [74,100]. In the ping pong cycle, there is cleavage of the 5’ or 3’ end of piRNA 
precursors via piRNA-Piwi complexes to generate functional piRNAs and silence transposon 
targets [36] .  The data from a variety of labs which suggest piRNAs exist in a variety of 
germline and somatic tissues (described above) suggest that piRNAs may exist in cells which 
do not express Piwi homologs.  This raises an interesting question:  how are piRNAs generated 
in absence of Piwi proteins?  It is possible that there is another as yet unidentified Piwi homolog 
in each of the tissues where piRNAs have been found.  Alternatively, there may be non-ping 
pong cycle mechanisms for piRNA generation that do not require Piwis. 
 
Figure 3.1 Murine Piwi orthologs are not expressed in mesenchymal stem cells 
Semi-quantitative RT-PCR on the 3 murine Piwi orthologs (miwi, miwi2, and mili) finds that 







Furthermore, piRNAs have recently been found in adult human brain and testes samples 
[101].  Intriguingly, a specific piRNA, piR_015520 has been identified in the human melatonin 
receptor 1A gene and exogenous expression of this piRNA is able to down-regulate melatonin 
receptor 1A gene transcript levels [101].  piR_015520 sits within intron 1 of the melatonin 
receptor 1A gene and is a sense piRNA.  This is the first report of piRNA-mediated regulation of 
a protein-coding gene, rather than a transposon repeat element.  Much more work must be 
done to determine additional piRNAs which correspond to gene sites and regulate gene 
expression, but these data suggest that piRNAs may be regulating gene expression (not only 
transposon expression) outside the germline and in human cells, suggesting that piRNAs 
regulate gene expression more broadly that previously thought.   
Rationale of the Study 
Because previous studies identified piRNAs in germline cells which express high levels 
of Piwi family members during development, it is thought that this class of small RNAs interacts 
exclusively with Piwis to exert their gene silencing effects.  Recently piRNAs have been 
identified in a variety of somatic tissues as well.  We asked whether piRNAs might also be 
present in our Hiwi over-expressing MSCs, although the parental MSCs do not express any 
mouse Piwi orthologs.  If piRNAs are present, we further queried if the populations would be 
different in Hiwi expressing MSCs (MSC-Hiwi 3 and MSC-Hiwi 7) compared to Hiwi non-
expressing MSCs (parental MSCs and MSC5).  Lastly, we asked whether a potential piRNA 
population would correspond to genic regions, transposon repeats or other genomic locations.   
Experimental Design 
In order to test for the presence of piRNAs in our Hiwi over-expressing we performed 
SOLiD sequencing on the entire small RNA population in our parental MSCs and MSC5 (do not 





(miRNAs) were filtered out, as were all small RNAs outside the known size range of piRNAs.  
The remaining piRNA reads were referenced against the piRNA bank database, although that 
contains only germline-derived piRNAs, to identify known piRNAs.  Novel putative piRNAs 
which met all other criteria but were not present in piRNA bank were also included in the 
analysis.  All piRNAs were then examined for genomic location.      
Results 
1. Small RNA sequencing reveals presence of piRNAs in mesenchymal stem cells 
piRNAs are expected to be present in tissues where Piwis are also present.  Our 
expectation was that piRNA would be present in the MSC-Hiwi 3 and 7 Hiwi over-expressors.  
Therefore, we were surprised to find that a piRNA population is present in both the MSC-Hiwi 3 
and 7 Hiwi over-expressors, but also in parental MSCs and MSC5 which do not express Hiwi.   
This suggests that a piRNA population may exist in a variety of tissues, including somatic 
tissues.  Moreover, the presence of Hiwi is not necessary for the existence of piRNAs.   
2. piRNA expression patterns do not shift in Hiwi-expressing cells 
After identifying the presence of piRNAs in parental MSCs and in Hiwi-expressing MSCs, we 
asked whether piRNAs are differentially expressed in Hiwi expressing MSCs compared to 
parental MSCs.  Previously, Kuramochi-Miagawa and colleagues [45] identified a characteristic 
shift in the piRNA population found in either wildtype or Mili/Miwi2 knockout mouse testes.  In 
order to test whether our Hiwi-MSCs show a characteristic shift in piRNA expression pattern, we 
compared the piRNAs in each of the MSC-Hiwi over-expressors with each of the Hiwi non-
expressing MSCs (Figure 3.2 A-D).  There are a few piRNAs which are highly expressed in 
Hiwi expressing MSCs compared to Hiwi non-expressing MSCs (Figure 3.2 A-D, above the top 
red line).  However, there is a similar number of piRNAs which are highly expressed in the Hiwi 





red line).  Moreover, the majority of piRNAs lie along the line x=y (within the red lines), 
suggesting that the piRNA expression patterns don’t shift significantly when Hiwi is over-
expressed.  Taken together, these data suggest that there is no characteristic shift in the piRNA 
populations in Hiwi expressing MSCs versus Hiwi negative MSCs; rather a few piRNAs are 
expressed more highly in the presence of Hiwi and others are expressed at lower levels.  There 
seems to be a shift in piRNAs in both directions in Hiwi-MSCs, though not in significant 
numbers. 
 
We then asked if the few differentially expressed piRNAs that we see (in both Hiwi 
expressing and Hiwi non-expressing MSCs) are true changes in piRNA expression or if they are 
due to clonal variation.  To test this, we compared both Hiwi negative MSCs to each other 
 
Figure 3.2 piRNA expression patterns do not shift in Hiwi-expressing cells 
(A-D) Comparison of the piRNA expression pattern in a Hiwi positive sample to that of a 
Hiwi negative sample.  (E) Comparison of the piRNA expression pattern in both Hiwi 
negative samples. (F) Comparison of the piRNA expression pattern in both Hiwi positive 
samples.  Red lines mark the line y=x; points outside the red lines represent differentially-






(Figure 3.2E) and both Hiwi expressing MSCs to each other (Figure 3.2F).  In these 
comparisons we find the vast majority of piRNAs are not differentially expressed (they sit inside 
the red lines).  There are a few piRNAs that sit outside the red lines, but these are very few 
compared to any of the Hiwi expressing MSC versus Hiwi non-expressing MSC analyses.  This 
suggests to us that the few differentially expressed piRNAs seen in Figure 3.2E, F are due 
simply to clonal variation rather than Hiwi expression.   
Our data indicate that, although there are a few piRNAs that are differentially expressed in 
the presence of Hiwi, there are just as many that are differentially expressed in Hiwi negative 
MSCs.  There is no characteristic shift in the piRNA expression patterns in the presence or 
absence of Hiwi.   
3. piRNAs in mesenchymal stem cells do not correlate to gene sites 
piRNAs in the germline are known to silence transposon repeat regions in order to maintain 
genome integrity.  However, a recent study has identified a piRNA which regulated expression 
of a protein-coding gene, rather than a non-genic repeat region [101].  To identify any gene 
 
Figure 3.3 Only two identified piRNA reads correspond to genes 
Two piRNAs found in Hiwi-MSCs correspond to genes.  One has a direct relationship 






regions to which piRNAs in our Hiwi-MSCs might correspond, we performed a bioinformatic 
analysis of the piRNAs and the mouse genome.  We found that there vast majority of piRNA did 
not correspond to gene loci.  There were only2 identified piRNA reads which correspond to 
genes (Figure 3.3).  These 2 genes are Fnip1 and Zbtb20.  The piRNA corresponding to Fnip1 
is upregulated in Hiwi-expressing MSCs and the Fnip1 gene itself is down-regulated in Hiwi-
expressing MSCs, suggesting a direct relationship of this piRNA with Hiwi.  On the other hand, 
the piRNA corresponding to Zbtb20 is expressed at low levels in Hiwi-expressing MSCs and the 
gene itself is also expressed at low levels in Hiwi-expressing MSCs, suggesting an inverse 
relationship of this piRNA with Hiwi.  Because these 2 piRNA-Hiwi relationships are opposing, 
and because the vast majority of piRNAs do not correspond to gene regions, we interpret these 
data to suggest that piRNAs likely do not generally regulate gene expression in our Hiwi-MSCs.  
Moreover, many piRNAs we identified correspond to repeat regions, though not directly to 
transposons.  The majority of piRNAs identified do not correspond to any known genome 
elements. 
4. piRNAs in mesenchymal stem cells do not generally lie upstream of gene sites 
After multiple analyses, we identified only 2 piRNAs which corresponded to potential target 
genes.  Since this approach identified such a small segment of the piRNA population, it is 
possible that these 2 piRNAs were identified by chance in our bioinformatic analyses.  To 
account for that, we broadened our analysis of differentially expressed piRNAs to include those 
that lie within 2 or 10 kilobases (kb) of transcriptional start sites (TSS) of potential target genes.   
Even with this relatively loose threshold, we identified only 5 additional piRNA reads that lie 2 or 
10 kb upstream of target genes (Figure 3.4).  Of these 5 piRNAs, only 1 sits within 2kb 






This piRNA is decreased in Hiwi-MSCs compared to parental MSCs and Mfsd11 is 
increased in Hiwi-MSCs, suggesting an inverse relationship of this piRNA with Hiwi.  We had to 
expand our analysis even farther, to 10kb upstream of TSS, in order to identify 4 additional 
piRNAs.  Of these 4, 2 have an inverse relationship with Hiwi and 2 have a direct relationship 
with Hiwi.  These 4 genes (Acsl1, Samd8, Gabbr1, Xpo7) have diverse roles (see Discussion).  
Taken together, the data from this less stringent analysis give only 5 additional piRNAs and 
target genes.  Moreover, the 5 piRNAs identified in this less stringent analysis reveal opposing 
piRNA-Hiwi relationships.  The vast majority of piRNAs, even examining up to 10kb upstream, 
do not correspond to gene regions. 
Discussion 
In this set of studies, we first asked whether piRNAs are present in our Hiwi-MSCs.  To 
our surprise, piRNAs were found, not only in Hiwi over-expressing MSCs (Hiwi-MSC 3 and 7), 
 
Figure 3.4 2 or 10kb upstream analysis reveals 5 piRNAs that lie upstream of 
genes 
5 piRNAs were found either 2kb (1 piRNA) or 10kb (4 piRNAs) upstream of TSS are 







but also in Hiwi non-expressing parental MSCs and MSC5.  While piRNAs have been most well-
characterized in germline cells during normal development, they have also recently been 
discovered in tissues outside the germline, including various fly and mouse tissues and in HeLa 
cells [79,80].  Our identification of piRNAs in MSCs is in line with these recent reports.  
Importantly, there is only one report of a piRNA which regulates a gene, rather than a 
transposon repeat region [101].   Similarly, we identified only 2 piRNAs which correspond to 
gene regions.  These 2 genes are Fnip1 and Zbtb20.  Fnip1 is a known folliculin-binding protein 
which has been associated with AMPK in the mTOR pathway [54,102] thought to be important 
for nutrient sensing.  However there is no direct evidence for any role it might play in cancer 
initiation or progression.  Zbtb20 is a transcriptional repressor, especially active in the fetal 
mouse liver [103].  A transgenic mouse model for Zbtb20 knock out shows metabolic 
dysfunction and defective hippocampus development [104,105].  There is no indication of 
tumorigenic growth in this mouse model of Zbtb20 depletion.   One recent study found that 
Zbtb20 expression is increased in hepatocellular carcinoma, and this correlates with a worse 
clinical prognosis [106].  However, in our tumorigenic Hiwi-expressing MSCs, Zbtb20 gene 
expression is decreased, suggesting that Zbtb20 (or its cognate piRNA) does not play a role in 
the Hiwi-mediated sarcomagenesis described in Chapter 2.  Upon expansion of our analysis to 
identify piRNAs within 2kb of a gene’s TSS, we identified only one piRNA, whose potential 
target gene is Mfsd11.  This gene has no known function.  Further analysis of piRNAs within 
10kb of a gene’s TSS reveals 4 more piRNAs which lie within 10kb of 4 genes: Acsl1, Samd8, 
Gabbr1, Xpo7.  These 4 genes have diverse functions, though not all have been implicated in 
cancer.  Acsl1 plays a role in fatty acid degradation [107] but has not been shown to be involved 
in the progression of cancers.  Samd8 has no known function.  Gabbr1 is a Gamma-
aminobutyric acid (GABA) receptor subunit involved in synaptic transmission in the central 





decreased in nasopharyngeal carcinoma [109]. Gabbr1 is also decreased in our Hiwi-MSCs; 
however, there are no other reports of Gabrr1 in other cancers.  Xpo7 is an export protein for 
molecules through the nuclear pore complex [110].  Importantly, there have been no studies 
implicating Xpo7 in cancer.  Taken together, the data from our bioinformatic analyses reveal that 
very few piRNAs correspond to gene sites, even when regions up to 10kb upstream of gene 
sites are examined.  Moreover, the few piRNAs that were identified had opposing relationships 
with Hiwi and their potential target genes are generally not known to be involved in tumorigenic 
processes. 
Other groups have used a variety of methodologies to identify piRNAs in their systems, 
especially in the male germline.  Commonly, an RNA-immunoprecipitation (RNA-IP) approach is 
used to extract a piRNA population.  In this technique, an antibody against a Piwi protein is used 
to capture the Piwi and its associated bound small RNAs.  The small RNAs are then run on a 
gel to identify a piRNA population.  While some groups have had success with this approach, 
there are some drawbacks which made it less desirable for our studies.  Firstly, an RNA-IP 
approach requires an IP-quality antibody against the relevant Piwi protein.  There are currently 
no commercially available IP-grade antibodies against Hiwi.  We have found commercially 
available antibodies against Hiwi suitable for western blotting and IHC only.   Secondly, an 
RNA-IP approach requires that Piwi proteins are present in the tissue being examined for 
piRNAs.  Historically, piRNAs have been found in tissues which express Piwi proteins (ie, male 
germline).  However, our studies suggest that a piRNA population exists in MSCs, even though 
no Piwi proteins are expressed in those cells.  These data would have been missed with an 
RNA-IP approach.  Thirdly, our sequencing approach generates detailed sequence data which 
can be checked against reference genomes with relative ease.  We are utilizing an alternative 
experimental approach to further investigate the potential piRNA population in MSCs.  We are 





in that it circumvents the need for an IP-grade antibody against Hiwi and also that the over-
expression of tagged Hiwi can be used to identify not only Hiwi-associated small RNAs, but also 
any Hiwi-associated proteins.   
Our evidence that piRNA populations exist in both Hiwi expressing and Hiwi non-
expressing MSCs is surprising, but joins a growing body of evidence which finds piRNAs in 
tissues outside the male germline.  However, these data raise an interesting question as to the 
origin of piRNAs in MSCs (as we show) and in other tissues where Piwis are not present (as 
others have shown).  Because piRNA biogenesis is thought to occur via an amplification loop in 
which piRNA precursors associate with Piwi-piRNA complexes to be alternately cleaved at with 
5’ or 3’ ends, it is puzzling that a piRNA can exist in a cell without Piwi homologs.  Our data 
suggest that piRNAs do exist in the absence of Piwis, and others have shown piRNAs in other 
cell types as well.  Perhaps there is a still unidentified Piwi homolog present that can account for 
the presence of these piRNAs.  Alternatively, there may be a non-ping pong-related mechanism 
for piRNA biogenesis.  Our data and that of other groups identifying piRNAs in a variety of cell 
types open up a new set of questions in which piRNA origins may have to be reevaluated and 
further investigated.  No matter how piRNAs are generated in the absence of Piwis, it seems 
that piRNAs are much more widespread that Piwi expression.  This suggests that although 
piRNAs are present in a variety of cell types, they are only able to exert their silencing effects 
where Piwis are also present (in the germline during normal development and in cancer during 
aberrant tumor development).  Moreover, our data indicate that there is no characteristic shift in 
piRNA expression patterns between the Hiwi expressing and Hiwi non-expressing MSCs.  
Lastly, we have found that piRNAs in MSCs generally do not correlate to gene regions.  Taken 
together, these data suggest that while piRNAs are present in MSCs, they do not shift in 





Materials and Methods 
Semi-quantitative RT-PCR 
RNA was extracted from the indicated cell lines or from adult mouse testis tissue, using the 
RNeasy kit (Qiagen).  1 µg of RNA was transcribed into cDNA using Super-Script III First Strand 
Synthesis System for RT-PCR (Invitrogen). To assess the expression levels of miwi, miwi2, mili 
and β-actin control semi-quantitative RT-PCR reactions containing Platinum Blue PCR mix 
(Invitrogen), 1ul cDNA and corresponding primers were run at the following PCR program: 95°C 
x 2min; 95°C x 30s, 55°C x 30s, 68°C x 45s for 28 cycles; 68x5min.  Experiments were 
performed in triplicate.  Primer sequences were as follows: miwi: F: 
TCGCAGGATTCGTCGCCAGC, R: CCCGCGGTCCTGAAAGACGC; Miwi2: F: 
TTGTCCCTGTGGCCTGGGTTTG, R: AGAACGGTCTCATTGCGGAGGAC; mili: F: 
GCAAGGCTCCGGCACAGTCC, R: GTGGGCCCCCTGAACAACGG. 
Small RNA sequencing 
Small RNA sequencing was performed by Dr. Palomero and colleagues at the CUMC Genomics 
Core Facility.  RNA samples were PCR-amplified with barcode tags.  These amplicons were run 
on the SOLiD 3+ platform for sequencing.  Initial bioinformatic analysis was performed by Dr. 






4. Chapter 4: Characterization of Hiwi-dependent epigenetic 
mechanism of tumorigenesis  
Piwis and DNA methylation 
In all model systems examined, Piwi family members are expressed in stem cells, 
including germ and hematopoietic stem cells, and are essential for germ line and/or somatic 
stem cell self-renewal [2,28,29,30]. Although the exact mechanism is still unclear even in the 
most well-studied models (e.g., drosophila, mice  [2,28,29,30]), Piwi appears to ensure stem cell 
maintenance by inhibiting transposon migration [36,58] during early development via an indirect 
(since Hiwi has no known direct chromatin modifying function)  increase in DNA 
methylation[55,59,60]. Specifically, previous studies have shown that transposon-specific DNA-
methylation was reduced and transposon activity was elevated following silencing of Hiwi (or its 
homologs). Although transposons promote evolutionary diversity in lower organisms, their 
unchecked migration in higher organisms can result in disruption of genomic integrity [61] and 
thus Piwi proteins may have developed as an evolutionary defense system for multi-cellular 
species [58].  However, neither the precise epigenetic mechanism which leads to DNA 
methylation-based silencing, nor the exact epigenetic silencing machinery which may be 
involved in this increase in of DNA methylation have been explored.    
Rationale of the Study 
 Because Piwi family members in well-studied model systems (Drosophila, mice) are 
known to silence transposons via DNA methylation-based mechanisms, we asked if this might 
also apply to our Hiwi over-expressing MSCs and our sh-Hiwi-MFH knock down cells. If DNA 
methylation is the mechanism by which Hiwi-expressing cells mediate sarcomagenesis, we 
further queried if treatment with a DNA de-methylating agent would be able to reverse Hiwi’s 






 To address a DNA methylation-based mechanism for Hiwi-mediated sarcomagenesis, 
we first assessed the global DNA methylation levels and expression levels of common 
transposon elements in our Hiwi MSCs.  We then performed a promoter methylation array to 
examine which promoters specifically might be altered by Hiwi-dependent DNA methylation.  
We also assayed for changes in the expression of DNA methyltransferase proteins in our Hiwi-
MSCs via western blotting.  Next, we asked whether treatment with a DNA de-methylating 
agent, 5-azacytidine, is able to reduce the colony forming capacity of Hiwi-expressing MFH 
sarcoma cells.  We also performed gene expression analyses of dox-ind-sh-Hiwi-MFH Hiwi 
knock down and 5-aza-cytidine treatment to see if they may be similar in terms of gene 
expression changes.  Lastly, we performed an in silico analysis of 3 gene expression profile sets 
(Hiwi-MSCs, sh-Hiwi-MFH knockdown and 5-aza-cytidine treatment) in order to identify a 
specific tumor suppressor gene which is aberrantly silenced in our model system.  Lastly, we 
return to our human primary sarcoma TMA and show that tumor suppressor expression in 
inversely correlated with Hiwi expression. 
Results 
1. Transposon expression is decreased in Hiwi-expressing MSCs  
Based on data from a variety of model systems which find that Piwi mediates stem cell 
maintenance via DNA methylation, we decided to formally explore the DNA methylation status 
of our cells.  Since Piwis are known to silence transposon expression, we examined the 
expression of 2 common transposon elements, IAP and Line 1 in our Hiwi-MSCs (Figure 4.1).  
We found that while there is some baseline expression of IAP and Line 1 transposons in 
parental MSC and MSC5, this is dramatically reduced in Hiwi-MSC 3 and Hiwi-MSC 7, which 





methylation levels and these data would suggest that global DNA methylation levels decrease 
when Hiwi is expressed. 
 
2. Global DNA methylation correlates directly with Hiwi expression level 
We then decided to assay for global DNA methylation changes directly.  Global DNA 
methylation was assessed by an ELISA-like assay, using an antibody against 5-Methyl 
Cytosine, which detects cytosine methylation at both CpG sites and non-CpG sites.  Global 
DNA methylation was significantly increased (approximately 40%, p<0.05; Figure 4.2A) in Hiwi-
expressing MSCs (Hiwi-MSCs) as compared to non-Hiwi-expressing MSCs (pMSCs & MSC5); 
suggesting that Hiwi expression leads to increase in DNA methylation.  Similarly, we observe a 
  
Figure 4.1 IAP and Line1 transposon expression decreases in Hiwi expressing 
MSCs 






significant decrease in global DNA-methylation (approximately 70%, p<0.05; Figure 4.2B) 
during Hiwi down-regulation via doxycycline induction in sh-Hiwi-MFH. 
  
We then checked whether the Hiwi-mediated increase in global DNA methylation is 
reversible with the DNA-methyltransferase inhibitor, 5-azacytidine (Vidaza).  Indeed, 5-
azacytidine treatment of Hiwi-MSCs completely (100%, p<0.05) reverses the increase in global 
 
Figure 4.2 Global DNA methylation is increased in Hiwi-MSCs 
 (A) Global DNA methylation is increased in Hiwi-MSCs. Error bars represent standard 
error. *= p<0.05 by Student’s T Test (B) Global DNA methylation is decreased in induced 
sh-Hiwi MFH cells. Cells were induced with doxycycline for 3 days before DNA was 
collected and assayed. Error bars represent standard error. *= p<0.05 by Student’s T 
Test (C) Global DNA methylation is decreased to non-detectable levels (ND) after 18h 
treatment with 10uM 5-azacytidine in Hiwi-MSCs. Lower doses of 5-azacytidine 
(including 1uM) did not change DNA methylation levels.  Error bars represent standard 






DNA-methylation mediated via Hiwi (Figure 4.2C) suggesting that DNMTs may be crucial 
intermediaries in Hiwi-mediated methylation. Of note, we did not observe any decrease in global 
DNA methylation following treatment of non-Hiwi-expressing MSCs with 5-azacytidine (data not 
shown), which may be reflective of the lower baseline global DNA methylation levels in those 
cells. 
3. DNA methyltransferase proteins are elevated in Hiwi-expressing MSCs 
Having established a direct correlation between Hiwi, DNA methylation, and Hiwi-associated 
DNA methylation reversibility via DNA-methyltransferase inhibitors, we next examined the levels 
of proteins known to modulate DNA methylation: DNA methyltransferase 1 (DNMT1), DNA 
methyltransferase 3 (DNMT3a), and methyl-binding protein 2 (MBD2). All three were found to 
increase in the presence of Hiwi (Figure 4.3). Interestingly, we find no expression of DNMT3b in 
Hiwi-MSCs.  Our data are the first to show that expression of DNMTs correlates with Hiwi 
 
Figure 4.3 DNA methyltransferase proteins are elevated in Hiwi-MSCs 
Western blots of indicated proteins reveal increased expression of DNMT1, DNMT3a 





expression, providing a potential explanation of the increased DNA methylation found in Hiwi-
expressing MSCs.  However, the exact mechanism by which Hiwi expression leads to an 
increase in DNMT expression is still unclear.  Moreover, we are unable to glean any further hint 
of mechanistic insight from developmental studies of Piwi proteins (which are much more 
thoroughly investigated) since the mechanism of Piwi is unknown in those developmental 
models  [2,28,29,30,36,55,58,59,60]. 
4. 5-azacytidine treatment restores transposon expression in Hiwi-expressing MSCs 
Since we have we shown that treatment of Hiwi-MSCs with 5-azacytidine can decrease 
global DNA methylation levels (Figure 4.2), we then asked if 5-azacytidine treatment is able to 
reverse the Hiwi-dependent transposon silencing we have previously observed (Figure 4.1).  5-
azacytidine is a DNA de-methylating agent which has been clinically approved for the treatment 
of myelodysplastic syndrome and acute myeloid leukemia [111] and is currently in clinical trials 
for a variety of disorders, reviewed in [112],  We found that indeed 5-azacytidine treatment can 
reverse Hiwi-mediated transposon silencing (Figure 4.4A), restoring IAP and Line1 transposon 
expression back to levels comparable with parental MSCs as the concentration of 5-azacytidine 
increases.  No such changes in transposons were observed in non-Hiwi expressing cells, 
pMSCs and MSC5. We further show that treatment of Hiwi-MSCs with either 5-azacytidine or 5-
aza-2-deoxycytidine can reverse Hiwi-mediated transposon silencing (Figure 4.4B, C).  5-
azacytidine treatments at lower concentrations (5uM or 10uM) show some restoration of Line1 
transposon expression (Figure 4.4B, red box).  However, a higher concentration of 5-
azacytidine treatment (50uM) is able to restore both IAP and Line1 transposon expression to 
levels comparable with parental MSCs, best seen for MSC-Hiwi7 (Figure 4.4C, red box) which 
has higher baseline Hiwi expression (Chapter 2) and is more tumorigenic (Chapter  2).   No 
such changes in transposons were observed in non-Hiwi expressing cells (Figure 4.4B,C, left 





50uM was highly toxic to the cells, despite our repeated treatment attempts.  Taken together, 
these data suggest that treatment with a DNA demethylating agent is able to restore transposon 







Figure 4.4  5-azacytidine treatment restores transposon expression in Hiwi-MSCs 
in a dose-dependent manner 
(A) Treatment of Hiwi expressing MSCs with 0uM, 5uM, 10uM, or 50uM 5-azacytidine for 
18h followed by IAP and Line1 quantitative RT-PCRs. Parental MSCs of each 5-
azacytidine concentration were used to normalize the rest of the samples at that 
concentration.  Error bars represent standard error. (B) Semi-quantitative RT-PCR for 
Line1 and IAP transposon expression on Hiwi-MSCs treated 18h with the indicated 
concentration of 5-azacytidine.  Actin is a loading control. (C)  Semi-quantitative RT-PCR 
for Line1 and IAP transposon expression on Hiwi-MSCs treated 18h with 50uM of 5-
azacytidine or 5-aza-2-deoxycytidine.  Actin is a loading control. All experiments were 






5. 5-azacytidine treatment reduces colony forming capacity of sarcoma cells 
We have shown that treatment with a DNA de-methylating agent, 5-azacytidine, is able to 
reverse Hiwi-dependent transposon silencing. We then asked if 5-azacytidine treatment can 
reverse another Hiwi-dependent cellular effect:  the colony forming capacity of MFH sarcoma 
cells.   Indeed, 5-azacytidine treatment of sh-Hiwi MFH cells (in the absence of doxycycline) 
results in elimination of colony formation (Figure 4.5A), similar to that seen in doxycycline-
induced sh-Hiwi MFH (Chapter 2). Importantly, colony formation was significantly reduced, 
even at a 1uM dose of 5-azacytidine.  Although higher doses were tested (data not shown), 
here we show the lowest effective dose. Colony formation during 5-azacytidine treatment was 
reduced to about 50% of untreated control for both sh-Hiwi-MFH clone C and sh-Hiwi MFH 
clone E (combined p<0.01 for both clones) (Figure 4.5B). Of note, we previously published on 
the general insensitivity of sarcoma cell lines to 5-azacytidine treatment [113], but now suggest 
that Hiwi expressing tumors may be an exception. Taken together these results indicate that 






6. Gene expression changes during 5-azacytidine treatment and during Hiwi knock 
down are very similar 
Global DNA methylation decrease and growth delay (colony formation) are common to both 
Hiwi down-regulation and DNA-methyltransferase inhibitor treatment, but to address whether 
the specific mechanism is the same, we performed a temporal gene expression profiling 
(Affymetric U133 Plus 2.0 Arrays) on sh-Hiwi MFH cells after Hiwi down-regulation (via 
doxycycline induction) or 5-azacytidine treatment. Using unsupervised hierarchical clustering of 
the whole gene sets of both conditions, we find that early time points (24-48hrs) of Hiwi down-
regulation associate with early time points (24-48hrs) of 5-azacytidine treatment, and similarly, 
longer down-regulation (4-7d) of Hiwi associates with longer treatment with 5-azacytidine 
(Figure 4.6A). We imported the Broad GSEA Gene Sets (Cytogenetic, Functional, Regulatory, 
 
Figure 4.5  5-azacytidine treatment reduces colony forming capacity of sarcoma 
cells 
(A) Untreated sh-Hiwi MFH cells or treated with 1uM 5-azacytidine at 4 weeks in colony 
forming assay. 5-azacytidine treatment decreases colony formation capacity. Combined 
p<0.01 by Student’s T Test. All experiments were performed in triplicate. Representative 
pictures shown at 20X magnification. (B) Quantification of colonies formed in either 
untreated sh-Hiwi-MFH or treated for 4 weeks with 1uM 5-azacytidine.  Averages of 4 







Neighborhood and Gene Ontology) into GeneSpring and comparatively analyzed the expression 
patterns of MFH cells at 24 hours treated with either 5-azacytidine treatment or dox-ind-sh-Hiwi-
MFH at 1, 2, 4 or 7 days under similar treatments.  Using a standard GSEA FDR (q value) of 
0.25 we were unable to identify any differentially expressed gene sets. 
Overlap of differentially expressed genes in both array sets shows that at early time points 
(Figure 4.6B), 75% of the genes that are differentially expressed following Hiwi down-regulation 
are also differentially expressed during 5-azacytidine treatment; and over 99% of these 
overlapping gene changes trend similarly. At later time points (Figure 4.6C), 50% of the genes 
that are differentially expressed following Hiwi down-regulation are also differentially expressed 
following 5-azacytidine treatment, with 93% of these overlapping gene changes trending 
similarly. These data suggest that 5-azacytidine treatment of MFH cells mimics Hiwi down-






7. Promoter methylation is unchanged by Hiwi expression 
The methylation of promoter region DNA is widely accepted as an epigenetic marker of 
transcriptional repression.  The promoter region of a gene can vary, but it is generally 
considered to be the region upstream of the gene’s transcriptional start site.  An increase in the 
DNA methylation of the promoter region is an important mechanism for stable silencing of that 
gene.   CpG islands are CpG-rich areas of 200bp to several kilo-bases in length, usually located 
in or near the promoters of highly expressed genes.  Increased methylation of CpGs within the 
 
Figure 4.6 Similar gene expression profiles for 5-azacytidine treatment and Hiwi 
knock down 
(A) Gene expression profiles of sh-Hiwi MFH cells treated with 1uM or 5uM 5-
azacytidine cluster with gene expression profiles of doxycycline-induced sh-Hiwi MFH 
cells, using the whole gene set from both treatments. Each column corresponds to 4 
samples: two clones (HpC and HpE), each run in replicate at the indicated time and 
treatment. (B) Venn diagram of overlapping differentially expressed genes in both dox-
ind-sh-Hiwi MFH cells and in 5-azacytidine-treated sh-Hiwi-MFH cells at early time 
points.  (C) Venn diagram of overlapping differentially expressed genes in both dox-
ind-sh-Hiwi MFH cells and in 5-azacytidine-treated sh-Hiwi-MFH cells at late time 





promoter region of tumor suppressor gene genomic DNA is a common epigenetic feature 
associated with tumorigenesis, and results in gene silencing [114,115,116].  
Upon observing a significant increase in global DNA methylation in Hiwi expressing MSCs 
(Figure 4.2A), we then asked which specific promoters might be affected by this increase in 
DNA methylation.  In order to answer that question, we examined the methylation changes in 
27,000 CpG islands covering 14,495 genes  that occur during Hiwi down-regulation in 
doxycycline-inducible sh-Hiwi MFH cells using  Illumina Meth27 arrays before and after 2, 4 and 
7 days of doxycycline induction.  Despite our data showing that global DNA methylation directly 
correlates with Hiwi expression (Figures 4.2 and 4.3), no overall change in CpG island 
methylation was observed following Hiwi down-regulation (Figure 4.7A). We did identify 18 CpG 
islands that decreased by at least 10% (i.e., beta>0.1) (Figure 4.7B) following Hiwi down-
regulation after 7 days in both of our doxycycline-inducible sh-Hiwi MFH clones C & E (no 
significant changes in DNA methylation were observed at earlier time points).  
We then asked if the methylation changes in the CpG sites of the 17 genes identified in 
Figure 4.7B correlate with gene expression changes observed in dox-ind-sh-Hiwi MFH cells.  
However, the 17 genes associated with these 18 CpG islands did not show a simultaneous 
increase in gene expression following Hiwi down-regulation (Figure 4.8A) nor did they show a 
consistent decrease in Hiwi-MSCs as compared to parental MSCs (Figure 4.8B). The p-values 
of the differentially expressed genes show they are indeed statistically differentially expressed 
(Figure 4.9A, B). And finally an equal number of CpG islands can readily be observed that gain 
CpG methylation following Hiwi down-regulation (Figure 4.7A). These data suggest that CpG 
methylation status of genes (at least the 14,495 on the Illumina Meth27 array) are not affected; 
and thus that the overall change in global DNA methylation observed may be accounted by 







Figure 4.7 Promoter methylation is not globally shifted during Hiwi knock down 
(A) Meth27 Illumina array of methylation of 27000 CpG site changes in sh-Hiwi MFH 
cells uninduced (x-axis) or induced with doxycycline for 7 days (y-axis).  Graph shows 
all CpG islands and reveals no global shift in CpG methylation. (B) Analysis of Illumina 
Meth27 promoter methylation arrays reveals only 18 CpG sites that show at least a 
10% decrease in methylation after 7 days of doxycycline treatment of sh-Hiwi MFH 









Figure 4.8 CpG methylated genes do not correlate to genes expression 
changes in sh-Hiwi MFH cells and Hiwi-MSCs 
(A)  Gene expression profiles of the 17 identified genes with CpG site hypo-
methylation, after 0, 2, 4 or 7 days of doxycycline induction of sh-Hiwi MFH cells. 
While corresponding CpG sites are hypo-methylated, there is no corresponding 
increase in gene expression. (B) Gene expression profiles of the 17 identified genes 
with CpG site hypo-methylation in Hiwi-MSCs.  Conversely, there is no decrease in 
expression of these genes.  Because each of the 17 identified genes contains 
multiple spots on the array, corresponding to multiple Gene IDs, multiple rows for 







8. Identification of methylation-dependent tumor suppressors via gene expression 
profiling 
To explore further the potential relationship between Hiwi associated DNA methylation and 
the resultant effects on genes we performed global gene expression analysis and subsequently 
focused on a group of tumor suppressor genes (TSGs)  [117] that were at least 1.5 fold: (1) 
down-regulated in Hiwi-MSCs as compared to parental MSCs; (2) up-regulated  in dox-ind-sh-
Hiwi MFH cells following 7 days of doxycyline; and (3) to ensure that these genes were DNA 
methylation dependent, further up-regulated following 5-azacytidine treatment of MFH cells 
(Figure 4.10A).  This overlap gave rise to 19 genes (Figure 4.10B). In each case of the three 
analyses in Figure 4.10A, the 1.5 fold differential fold expression was chosen as the 
discriminator. There was no statistical significance associated with fold change. Each of the 
three was then independently overlapped. Thus there is by definition no associated p-value. 
 
 
Figure 4.9 P-values of differentially expressed genes identified in CpG 
promoter methylation array 
(A) p-values of differentially expressed genes identified in Figure 4.8A.  (B) p-





Since Rb1 was identified in this set and its methylation has been thoroughly studied, we 
further assayed its promoter methylation via bisulfite sequencing as well as the Line1 regulatory 
element (Figure 4.11). In agreement with our CpG promoter methyl array results, there are no 
changes in the methylation status of the Rb1 promoter CpG sites as Hiwi levels change (Figure 
4.11, middle and bottom graphs).  Additionally, we find that the methylation of Line1 transposon 
CpG sites also remain unchanged as Hiwi level change (Figure 4.11, top graph).  These data 
suggest that because no methylation changes occur in these methylation-dependent genes, 
Hiwi-associated DNA methylation increase that we observe is likely promoter non-CpG site 







Figure 4.10 Assessment of Hiwi target genes 
 (A) Top panel: Affymetrix 430 2.0 array of gene expression changes in parental 
MSCs (x-axis) or Hiwi-MSCs (y-axis).  Affymetrix U433 array of gene expression 
changes in sh-Hiwi MFH cells uninduced (x-axis) or induced for 7 days with 
doxycycline (y-axis) (middle panel) or untreated (x-axis) and after 7 days of 1uM 
5-azacytidine (y-axis) (bottom panel).  Arrow indicates genes used in overlap 
analysis.  (B) Overlap of Tumor Suppressor Genes (TSG) as described.  All 19 
overlapping TSGs are listed here. Each comparison consists of two clones in 








We went on to further examine the methylation of Line1 and IAP transposon regions before 
and after treatment with 5-azacytidine in Hiwi-MSCs (Figure 4.12).  Although bisulfite 
sequencing of the Rb1 promoter and of Line1 did not show any changes in CpG methylation in 
Hiwi-MSCs, we performed additional quantitative PCRs followed by bisulfite conversion on Hiwi-
MSCs that were treated with 5uM, 10uM or 50uM 5-azacytidine for 18h. There are no significant 
 
Figure 4.11 Methylation of Rb1 and Line1 promoters do not change as Hiwi levels 
change 
Bisulfite sequencing of Rb1 promoter CpGs in Hiwi-MSCs (top graph) and in sh-Hiwi 
MFH cells (middle graph) reveal no methylation changes as Hiwi levels change.  
Similarly, bisulfite sequencing of Line1 CpGs in Hiwi-MSCs (bottom graph) reveal no 







changes in the methylation of these transposon regions in the Hiwi-MSCs.  These quantitative 
PCR data of IAP and Line1 are in line with our bisulfite sequencing data for both Line1 and Rb1 
(Figure 4.11), suggesting that global DNA methylation increases in Hiwi-MSCs, but not at sites 
that are local to Line1 and IAP (just as with Rb1). The methylation of these regions remains 
unchanged during 5-azacytidine treatment, further suggesting that Hiwi-associated methylation 
is non-CpG methylation.    In agreement with our promoter CpG methyl array (Figure 4.7), no 
methylation changes at any CpG islands (increase or decrease) in these DNA methylation 
dependent genes were observed (Figure 4.8).   
 
9. Cyclin dependent kinase inhibitor expression is altered in Hiwi-expressing cells 
Since cell cycle genes were over-represented in the 19 TSGs selected, and upon further 
examination several additional cyclin dependent kinase inhibitors (CDKIs) could be identified 
immediately below our previously described threshold, we further focused on CDKIs p21, 
 
Figure 4.12 Line1 and IAP transposon methylation is unchanged in Hiwi-MSCs 
Quantitative PCR of IAP or Line1 transposon expression, followed by bisulfite 
conversion, on parental MSCs, MSC5, Hiwi-MSC3 and Hiwi-MSC7 treated with the 
indicated concentration of 5-azacytidine for 18h.  Experiments were performed in 






p27 and p15.  Now that we had identified CDKIs as genes which are sensitive to Hiwi-
associated DNA methylation by our in silico methods, we wanted to validate the above 
CDKIs as responsive at the protein level to Hiwi. CDKIs decrease in Hiwi-MSCs and 
increase in sh-Hiwi MFH upon doxycycline induction (Figures 4.13A, B). 
  
We further performed IHC on the human sarcoma tissue microarray used to assess Hiwi 
(Figure 2.1); and show that p15, p21, and p27 show a tight IHC-based inverse correlation to 
Hiwi levels (Figure 4.14).  Ten cases of each subtype (present in triplicate) were scored from 0 
to 3 blindly by sarcoma pathologists for each of the indicated proteins. Average scores are 
plotted here.  Importantly, another CDKI, p16, which was not identified in our screen, does not 
show such a correlation at the IHC level. Previous analyses have only inversely linked p27 to 
 
Figure 4.13 CDKIs are decreased in Hiwi-MSCs 
 (A) Western blot of indicated proteins reveals that p21 and p27 are decreased in Hiwi-
MSCs.  (B) Western blot of indicated proteins reveals that p21, p27 and p15 are 






sarcoma grade [118]. Thus our demonstration of an inverse relationship to Hiwi for p15, p21 and 
p27, combined with our functional data, leads us to conclude that our observations in model 
systems apply to human sarcomas.  
 
10. Histone methylation marks remain unchanged during Hiwi knock down 
Our inability to detect any DNA promoter methylation via sequencing at either the Line1 
element or at the Rb promoter (two transcripts heavily regulated by Hiwi) (Figure 4.11) leads us 
to suggest that promoters are not methylated.  We then asked if other epigenetic modifications, 
besides promoter DNA methylation, might be altered in our sh-Hiwi-MFH cells. On this note a 
recent report by Sugimoto et al [119] found that another Hiwi family member, Hiwi2, induces p16 
silencing via histone 3 lysine 9 methylation, but not, however, gene promoter DNA methylation.  
 
Figure 4.14 CDKIs have an inverse relationship with Hiwi in primary human sarcomas 
IHC analysis of a human sarcoma TMA reveals a tight inverse correlation of p21, p27 and 
p15 expression (x-axes) to Hiwi expression (y-axis) (R2=0.764; R2=0.8679; R2=0.7539, 
respectively) but no such correlation for p16 expression (x-axis) to Hiwi expression (y-axis) 
(R2=0.5418). Ten cases of each subtype (present in triplicate) were scored from 0 to 3 blindly 







To examine the possibility of Hiwi-mediated histone methylation changes, we performed 
immunofluorescence staining for various histone marks (Figure 4.15A-F) on our dox-ind-sh-
Hiwi MFH cells. However, we were not able to discern any alterations in any histone marks 
examined during Hiwi down-regulation, although we do not doubt that just as reported by 
Sugimoto et al, promoters of silenced genes will be associated with silencing chromatin marks.  
We acknowledge that these are global analyses which examine histone marks at a low 
resolution.  However, without discernible changes in a specific histone mark identified in this 
screening approach, we were unable to move forward with targeted analyses in a lead 







11. Determining methylated loci via STAMP assay  
Taken together, our data suggest that global DNA methylation increases as Hiwi expression 
increases, but not at promoter regions.  In order to identify which regions are methylated in Hiwi-
expressing cells, we have undertaken a collaboration with the Scandura Lab (Weill Cornell 
Medical College).  An assay developed in the Scandura lab, called a STAMP assay [120] 
(Sequence Tag Analysis of Methyation Patterns) is used to map methylated DNA regions to a 
 
Figure 4.15 Epigenetic histone marks are unchanged in doxycycline-induced sh-Hiwi-
MFH cells 
Epigenetic histone marks are unchanged in doxycycline-induced sh-Hiwi MFH cells.  
Immunofluorescence on sh-Hiwi MFH cells, either uninduced or induced for 7days with 
doxycycline to knock down Hiwi levels, for the following histone 3 lysine or arginine marks (A) 







reference genome in order to identify highly methylated genomic loci.  We have employed this 
technique in our sh-Hiwi-MFH cells, either uninduced, or induced with doxycycline to down-
regulated Hiwi.  Preliminary data suggest that there are about 200 differentially methylated 
regions in dox-induced sh-Hiwi-MFH cells, however, there is little correlation of these regions to 
gene expression changes.  Because these data are highly preliminary and represent a non-
comprehensive analysis of the genome, we are continuing to analyze these data rigorously.  
This work in on-going in both our lab and in the Scandura lab.    
Discussion 
 Using primary mesenchymal stem cells, MFH sarcoma cells, and human tumor samples 
we show here that Hiwi mediated tumorigenesis is associated with global DNA-
hypermethylation and is reversible using DNA-methyltransferase inhibitors.  We also show that 
Hiwi associated global DNA-hypermethylation occurs at non-promoter CpG regions.  
Additionally, Hiwi levels correlate inversely with levels of known tumor suppressor genes, 
specifically CDKIs. To the best of our knowledge, this is the first mechanistic examination of 
Hiwi functionality in a mammalian cancer context. Our studies reveal not only a novel oncogenic 
role for Hiwi as a driver of tumorigenesis (Chapter 2), but also that the use of epigenetic agents 
such as 5-azacytidine may be clinically beneficial for treatment of tumors that express Hiwi. Our 
data also show that Hiwi-mediated sarcomagenesis is associated with DNA hyper-methylation 
with subsequent genetic and epigenetic changes that favor a tumorigenic state, reconciling the 
outstanding conundrum of how Hiwi may act appropriately to promote genomic integrity during 
early development (via transposon silencing)  and inappropriately  during aberrant expression in 
adult tissues with subsequent tumorigenesis.  Our data are the first to reveal a connection 
between Hiwi expression in human cancers and DNA methylation. 
Despite the tight correlations between Hiwi expression, global DNA methylation, and 





exact genomic loci which are methylated in our models, we are currently working in 
collaboration with the Scandura lab at Cornell on a genome-wide methylation analysis assay.  
Additionally, because our studies are the first to link Hiwi expression in cancer with DNA 
methylation, it will now be interesting to evaluate the DNA methylation status of all Hiwi 
expressing cancers, including human primary undifferentiated sarcoma samples. In our models 
and others [73,121] Hiwi is predominantly cytoplasmic. Furthermore, the protein-level up-
regulation of DNMT1, DNMT3a and MDB2 (Figure 4.3) is post-transcriptional (RNA levels do 
not change in either Hiwi-MSCs compared to parental cells or in sh-Hiwi MFH before and after 
doxycycline induction, data not shown). These data together, and given previous reports of 
Hiwi's interaction with ribosomes [122] and its cytoplasmic localization, Hiwi-associated DNA-
methylation may involve as yet unidentified control of DNMT translation. The exact relationship 
between Hiwi and its mechanistic epigenetic control is an ongoing endeavor both in our 
laboratory within a cancer context and in the laboratories of many others interested in the role of 
Piwi proteins in development [2,28,29,30,36,55,58,59,60]. 
Even in mice, where Piwi orthologs have been more extensively studied in terms of DNA 
methylation [55,59], the exact mechanism by which Piwi family members mediate DNA 
methylation during normal embryological development is still unclear. Our data that (1) Hiwi 
translationally up-regulates DNMTs, (2) global DNA methylation (at CpG and non-CpG sites) 
correlate directly with Hiwi levels, (3) promoter CpG methylation does not change during Hiwi 
down-regulation and (4) Hiwi down-regulation and 5-azacytidine treatment are mechanistically 
similar, taken all together, suggest that Hiwi-associated DNA-methylation is occurring globally at 
non-CpG promoter areas and/or at repetitive element regions. Our inability to detect any DNA 
promoter methylation via sequencing at either the Line1 element or at the Rb promoter (two 
transcripts heavily regulated by Hiwi) leads us to suggest that promoters are not methylated. 





distance gene silencing via chromatin remodeling [123,124] and given previous reports that Piwi 
proteins associate with piRNAs that share homology to repetitive elements [61,125] may explain 
the lack of gene promoter methylation observed in our systems. A recent report [119] suggests 
that Hiwi2, another Piwi protein, induces p16 silencing via histone 3 lysine 9 methylation, but 
not, however, gene promoter DNA methylation.  We examined possibility of Hiwi-mediated 
histone methylation changes during Hiwi knock down in MFH cells (Figure 4.15A-F), but 
histone methylation remains unchanged.  We are aware that immunofluorescence (IF) is 
perhaps a low resolution method to detect histone methylation changes.  However, using this IF 
methodology to screen through many histone marks, we were unable to identify a lead to carry 
further to more time-intensive high-resolution types of analysis, such as western blotting for 
post-translational histone marks [126] or Chromatin Immunoprecipitation-sequencing (ChIP-seq) 
[127] to identify histone marks and which genomic elements they associate with.  Without a 
substantial lead histone modification to investigate further, we interpret our data to suggest that 
Hiwi does not mediate histone methylation marks during doxycycline-induction of Hiwi 
knockdown in MFH sarcoma cells.  Regardless, we believe that stringent statistical cut-offs and 
the overlapping of gene lists from several independent analyses, clones, and model organisms, 
resulted in a gene list that likely belies the true extent of gene silencing found in Hiwi expressing 
cancers. The identified genes are likely to be extremely specific and serve as the basis for 
further studies of Hiwi mediated gene regulation, tumorigenesis and DNA methylation.  
Our observation that Hiwi-mediated tumorigenesis is associated with increased global DNA 
methylation is somewhat discordant from the more widely accepted notion that global 
methylation levels are decreased in a variety of human cancers despite specific increase in both 
promoter and non-promoter CpG island methylation.  Thus the global hypomethylation observed 
in cancer is believed to predominantly occur via repetitive element hypomethylation (which 





result of its inherent developmental preference for repetitive element silencing via DNA 
methylation, Hiwi may preferentially target repetitive elements for methylation in cancer cells 
thus mechanistically accounting for an exception to the commonly observed global 
hypomethylation of cancer. Ours are thte first data to examine DNA methylation levels in Hiwi-
expressing cancers. 
 Although many recent reports detect high levels of Hiwi in all cancers examined, none have 
addressed a role for Hiwi in cancers, nor do they investigate the mechanism by which Hiwi may 
be acting. The data presented here are, to our knowledge, the first to elucidate that DNA 
methylation dependent silencing of tumor suppressor genes accounts for the Hiwi-mediated 
tumorigenesis.  Moreover, we have identified a potential therapeutic avenue in which Hiwi 
expressing cancer cells treated with 5-azacytidine show reduced colony forming capacity and 
share many gene expression changes with Hiwi knock down cells.  This suggests a therapeutic 
rationale for treating patients with Hiwi-expressing tumors (which are sarcomas, but many other 







Materials and Methods 
Gene expression profiling 
RNA from the indicated cell lines were hybridized to Affymetrix HG U133 (human) or Affymetrix 
430 2.0 (mouse) oligonucleotide arrays per standard protocols of the Columbia Genomics Core 
Facility. Class-comparison analysis using two-sided Student t-tests identified mRNAs that were 
differentially expressed between indicated samples (p<0.05). Raw data will be deposited in the 
public repository.   
 
Promoter methylation profiling 
Promoter methylation profiling was done using Illumina Meth27 promoter arrays.  Samples were 
run at Roswell Park Cancer Institute Genomics Facility.  Average beta values, corresponding to 
amount of methylation, were then analyzed using Genespring software.  
 
Colony Formation Assays 
Cells were suspended in 0.3% agar (Sigma) in culture medium and plated into 6 well plates, 
with a base layer of 0.6% agar in culture medium. For doxycyline and 5-azacytidine treatments, 
cells were pre-treated for 7 days in culture before beginning colony formation assay.  Cells were 
kept in drug-spiked media during the assay and monitored for colony formation.  Pictures were 
taken after 4 weeks.  Experiments were performed in 2 times, each time in duplicate. 
 
Semi-quantitative RT PCR 
Total RNA was extracted from the indicated cell lines using RNeasy RNA extraction kit (Qiagen) 
according to the manufacturer’s protocol.  1 µg of RNA was transcribed into cDNA using Super-
Script III First Strand Synthesis System for RT-PCR (Invitrogen). To assess the expression 





Platinum Blue PCR mix (Invitrogen), 1ul cDNA and corresponding primers were run at the 
following PCR program: 95°C x 2min; 95°C x 30s, 55°C x 30s, 68°C x 45s for 28 cycles; 
68x5min.  Experiments were performed in triplicate.  
 
Assessment of DNA methylation levels 
Genomic DNA was isolated by DNeasy Blood and Tissue Kit (Qiagen).  Global DNA methylation 
levels were assessed by Methylflash Methylated DNA Quantification Kit (Epigentek) and read 




Total RNA was extracted from the indicated cell lines using an RNA extraction kit (Qiagen) 
according to the manufacturer’s instructions.  RNA was hybridized to Affymetrix U133Plus2 
arrays via Genomics Shared Resource at Columbia University and analyzed as previously 
described by us [9,10] and being submitted to NCBI GEO. Specifically, data was imported into 
GeneSpring and RMA (Robust Multi-array Analysis) was used to normalize and summarize 
probe-level intensity measurements (PM) corrected for background using a non-linear 
correction, done on a per-chip basis based on the distribution of PM values. Expression values 
were then quantile normalized. For RMA, the probe affinity effects are assumed to sum to zero, 
and the gene effect (expression level) is estimated using median polishing thus protecting 
against outlier probes. Hierarchical cluster analysis was performed using a Pearson correlation 
coefficient.  Gene ranking per subtype was performed using ANOVA (parametric test, Benjamin 
and Hochberg false discovery rate p<0.05, and Student-Newman-Keuls post hoc analysis). 
Statistical analysis to correlate stages of differentiation using analysis of variance and principle 





detail by us[9,10].  Broad GSEA Gene Sets (Cytogenetic, Functional, Regulatory, 
Neighborhood,a nd Gene Ontology) into GeneSpring and comparatively analyzed using a 
standard GSEA FDR (q value) of 0.25. 
 
Immunohistochemistry (IHC) 
IHC was performed as previously described by us[93]. Briefly, formalin-fixed, paraffin-embedded 
tissues were rehydrated and treated with citric buffer for antigen retrieval.  Slides were blocked 
with 10% horse of goat serum in 2% BSA-PBS and then incubated in primary antibody (diluted 
in 2% BSA-PBS) overnight at 4°C. Following 30 minutes of secondary antibody and tertiary 
antibody (Vector Labs) incubation, slides were developed with 3,3-Diaminobenzidine (DAB) and 
counterstained with Hematoxyalin. For cells, fixation was performed with 50% 
Methanol/Acetone for 10 minutes, then blocking, primary antibody incubation, and detection was 
performed as for FFPE IHC. Primary antibodies used in these studies:  Hiwi (Abcam, 12337); 
p15 INK4b (Novus Biologicals, NB100-91906); p16 (BD Pharmingen, G175-405); p21 (Santa 
Cruz, sc-6246); p27 (Santa Cruz, sc-528).  
 
Immunofluorescence (IF) 
Standard IF technique was used.  Briefly, cells were fixed in cold 1:1 Methanol-Acetone and 
blocked with 10% donkey serum in 2% BSA-PBS. The following primary antibodies were 
applied overnight at 4°C at 1 to 200 dilution in blocking buffer: H3K4me (abcam #ab8898); 
H3K4me (abcam #ab6000 );  H3K27me (abcam #ab6002); panH3Rme2 (abcam #ab413); 
H3R2me (abcam #ab80075); H3R17me (abcam #ab8284). 
 





The TMA contained 10 cases of each sarcoma subtype in triplicate.  For TMA analysis, IHC 
staining was scored on a scale of 0 to 2 by multiple sarcoma pathologists.  The average score 
for each sarcoma subtype was calculated and representative pictures are shown.  Scoring of 
the TMA for CDKI expression as compared to Hiwi expression used a scale of 0 to 3. 
 
Western Blotting 
Standard western blotting technique was used.  Briefly, protein lysate was collected from cells 
with RIPA buffer (Boston BioProducts) and 50ug were run on a 4-20% Tris-glycine gradient gel 
(Invitrogen).  Nitrocellulose membranes were incubated overnight at 4°C in primary antibody: 
DNMT1 (1:500, abcam 92453); DNMT3a (1:500, abgent AP1034a); MDB2 (1:1000, abcam 
38646); Hiwi (1:500 ProSci 45-735P). 
 
Bone and Fat Differention 
Bone or fat differentiation was assessed in MSCs after 21 days in bone or fat differentiation 
media, as previously published [9].  Approximate percentage of differentiated cells was 







5. Chapter 5: Conclusions and Future Directions 
In this set of studies, we use mesenchymal stem cells, sarcoma cells, a transgenic mouse 
model and primary human sarcoma samples to show that: (1) Hiwi is directly tumorigenic; (2) 
Hiwi-expressing tumors may be addicted to Hiwi expression; (3) Hiwi mediated tumorigenesis is 
associated with global DNA-hypermethylation and is reversible using DNA-methyltransferase 
inhibitors; (4) Hiwi associated global DNA-hypermethylation occurs at non-promoter CpG 
regions; and (5) Hiwi levels correlate inversely with levels of known tumor suppressor genes. 
This is the first mechanistic examination of Hiwi functionality in a mammalian cancer context. 
Our studies reveal not only a novel oncogenic role for Hiwi as a driver of tumorigenesis, but also 
that the use of epigenetic agents may be clinically beneficial for the treatment of tumors that 
express Hiwi. Additionally, our data show that Hiwi-mediated methylation is associated with 
DNA hyper-methylation with subsequent genetic and epigenetic changes that favor a 
tumorigenic state.  This explains how Hiwi may act appropriately to promote genomic integrity 
during early development (via transposon silencing) but inappropriately during its aberrant 
expression in adult tissues with subsequent tumorigenesis.  We have also identified the 
presence of piRNAs in parental MSCs and in Hiwi-expressing MSCs, though the presence of 
Hiwi does not cause a characteristic shift in the piRNA population.  We went on to analyze 
corresponding locations in the genome of these piRNAs and found that they generally do not 
correlate to gene regions.   
A novel oncogenic role for Hiwi 
In Chapter 2, we address a possible role for Hiwi in stem cell maintenance and/or 
sarcomagenesis.  We find that Hiwi is highly expressed in human primary sarcomas and that 
exogenous over-expression of Hiwi in sarcoma precursors (ie, mesenchymal stem cells) is able 





These data, along with our Hiwi knock-down model in MFH sarcoma cells, are the first to reveal 
a novel oncogenic role for Hiwi. 
Piwis have been studied in the fly (Piwi) and mouse (Miwi) germline.  During normal 
development, they are thought to be critical for maintenance of germline stem cells.  Over-
expression of Piwi in flies results in increased germline stem cell numbers, and loss of Piwi 
results in decreased germline stem cell numbers [32,33].  Similarly, mice which do not express 
Miwi or Mili show a block in spermatogenesis [44,73].  In exploring the stem cell maintenance 
role for Hiwi outside the germline, and in the context of adult tissue stem cells, we explore the 
capacity of mesenchymal stem cells which exogenously over-express Hiwi to differentiate down 
the adipocytic or osteogenic pathways, two typical mesenchymal lineages.  Hiwi-MSCs show a 
block in differentiation down both of these pathways, suggesting that Hiwi, when aberrantly 
expressed outside the germline—in this case in sarcoma precursor cells—inhibits differentiation 
and promotes sarcomagenesis.  In line with those data, conditional knock down of Hiwi in MFH 
sarcoma cells, derived from an undifferentiated sarcoma, results in re-establishment of 
osteogenic differentiation of the MFH cells.  Further supporting the suggestion that Hiwi inhibits 
differentiation and promotes sarcomagenesis is our data which finds Hiwi is most highly 
expressed in high grade undifferentiated human sarcomas (HGUS) but is expressed at much 
lower levels in well differentiated sarcoma subtypes. 
We have found also that Hiwi drives tumorigenesis, revealing a novel oncogenic role for 
Hiwi. When we began these studies [130], Hiwi was known to be highly expressed in sarcomas 
at the RNA level [26] and in gastric cancer [69].  Since the start of our investigations, many 
more reports have found high levels of Hiwi in a variety of cancers [65,66,67,96].  Importantly, 
all of these studies have focused on the clinical significance of Hiwi as a prognostic marker and 





expression promotes sarcomagenesis.  Similarly, conditional knock down of Hiwi reduces 
colony forming capacity, a common proxy for tumorigenic potential.  Because ours are the first 
data to examine Hiwi as a driver of tumorigenesis, rather than simply a prognostic marker, we 
also asked if there is a direct genetic basis for Hiwi up-regulation in cancer.  We found that there 
is no characteristic chromosomal amplification of Hiwi in Hiwi-expressing human sarcoma 
samples.  Hiwi cDNA has been independently isolated from several human cancers and 
developing sperm [64,69] without sequence divergence; thus although we cannot rule out a 
stabilizing mutation, it seems unlikely. Since part of the tumorigenic process involves a 
recapitulation of the embryonic state, similar mechanisms that up-regulate Hiwi during 
embryological development may result in Hiwi's up-regulation in cancer.  Regardless, our data 
suggest that Hiwi inhibits differentiation and promotes sarcomagenesis when expressed outside 
the germline, in a cancer context.   
Since our data are the first to suggest an oncogenic role for Hiwi, it will be critical to 
confirm that Hiwi acts similarly in the other cancers where it is highly expressed.  Another open 
question is what the genetic basis for Hiwi over-expression is in primary sarcomas, as well as 
other high-Hiwi cancers.  We have ruled out a chromosomal amplification of Hiwi in sarcomas, 
but an exhaustive sequencing effort of Hiwi in all cancers which express Hiwi might then be able 
to definitively discern any activating or stabilizing mutations.  Identifying the upstream pathway 
components which up-regulate Hiwi in cancers will also be critical to more specifically defining 
Hiwi’s oncogenic role, although analogous mechanisms which control Hiwi expression in germ 
stem cells during development are unknown.  One approach to parsing out upstream proteins 
which control Hiwi expression is to identify which transcription factors (other members of a 
protein complex) may be associated with the Hiwi gene, perhaps through an immobilized 





Presence of piRNAs in mesenchymal stem cells 
A large focus of piRNA research has been dedicated to elucidating their role in germline 
stem cells.  piRNAs were isolated from rodent testes by 4 different groups simultaneously 
[54,56,57,70], suggesting that this novel class of small RNAs were specific to male germline 
stem cells.  Additionally, the zebrafish Piwi homolog, Ziwi, is expressed exclusively in the gonad 
[71], further suggesting that the piRNA-Piwi pathway is specific to the germ-line.  However,  
piRNAs have been identified outside germ stem cells, including in somatic cells of the 
Drosophila ovary [78], in neurons of the mouse central nervous system [79], in HeLa cells [81], 
in adult human brain and testes samples [101] and even in mesenchymal stem cells[83].  The 
piRNAs associate with Mili in the cytoplasm of mesenchymal stem cells and are thought to be 
important for keeping cellular proliferation in check.  But, importantly, Wu and colleagues 
[83]examined Mili expression by immunoprecipitation (IP) and western blot using the same Mili 
antibody, suggesting that actual Mili expression is much lower than the enriched band shown. 
There was no evidence that other murine Piwi orthologs are present in mesenchymal stem cells.   
This likely gives the impression that Mili expression is much higher than would be otherwise 
identified.  It is possible that Mili is not even detectable without IP-western blot enrichment using 
the same Mili antibody.  Moreover, there was no western blot of Mili expression without IP 
enrichment, nor was there any evidence of Miwi and Miwi2 expression (the other murine Piwi 
homologs).  This is in line with our work which has shown that Mili, Miwi and Miwi2 are not 
readily detectable by RT-PCR from murine MSCs.   
Using a small RNA sequencing approach, we asked whether piRNAs are present in our 
Hiwi-MSCs or in our parental MSCs.  Because piRNAs are known to associate with Piwi 
proteins, we expected to identify piRNAs in our Hiwi-expressing MSCs.  But to our surprise, a 
population of piRNAs was also identified in our Hiwi non-expressing MSCs.  While this is not the 





mesenchymal stem cells that do not express any Piwi homologs.  This is in keeping with the 
previous identification of piRNAs in MSCs [83], since the Mili identified in those MSCs is likely 
only an experimentally-enriched band rather than true Mili expression. The other murine Piwi 
homologs were not detected at all.  Since our data suggest that piRNA expression can be 
achieved without Piwis in MSCs, this raises the question of how these piRNAs are generated in 
the absence of Piwi homolog expression.  It is possible that there is another still-unidentified 
Piwi homolog in MSCs that is responsible for a ping-pong cycle-like amplification loop to 
generate piRNAs.  Alternatively, there may be a non-amplification loop mechanism for piRNA 
biogenesis that has not yet been elucidated.  One way to approach the latter possibility is to use 
a mass spectrometry approach to pull out a biotinylated piRNA of interest and its associated 
proteins and then isolate the associated proteins for mass spectrometric analysis for 
identification.  However, this requires that there is already a specific piRNA of interest to focus 
on.  It may also be possible to use a pool of biotinylated piRNAs of interest rather than only one. 
Another related experiment is to exogenously transfect primary piRNA transcripts (available 
from Exiqon) into cells and then isolate the mature piRNAs with any associated proteins.    
Our piRNA data suggest to us that perhaps piRNAs are more widely expressed than 
previously thought.  piRNAs were also identified in our Hiwi-MSCs.  When the piRNA population 
in one Hiwi expressor is compared to the piRNA population in a Hiwi non-expressor, we find that 
there is no global shift in piRNA expression pattern.  This is in contrast to the kind of global and 
characteristic piRNA shift seen in Mili or Miwi null murine testis [45].  Moreover, we found that 
the vast majority of piRNAs do not correlate to gene regions, suggesting that they do not 
regulate gene expression.  This is in line with a large body of work which implicates piRNAs and 
Piwis in silencing of transposon repeat regions, but not genes [45,59,132].  In order to more 
exhaustively map the genomic locations of the piRNAs identified in our studies, we would like to 





transposons, etc.  Our initial bioinformatic analyses (Chapter 3) have confirmed that piRNAs in 
MSCs do not map to gene regions, and do not show any particular chromosome bias.  
However, a more extensive bioinformatic analysis to further correlate these piRNAs to other 
genomic elements will be critical to understanding the role of these piRNAs globally in MSCs.  
Interestingly, there has only been one report [101] of a specific piRNA, piR_015520, whose 
exogenous expression of this piRNA is able to downregulate a protein-coding gene: melatonin 
receptor 1A gene.  This is the first, and only, report of piRNA-mediated regulation of a protein-
coding gene, rather than a transposon repeat element and it has yet to be confirmed in 
additional studies.  Taken together, our data suggest that although there is a piRNA population 
present in parental MSCs in the absence of Miwi (or Miwi2 or Mili) expression, it does not 
regulate gene expression and piRNA expression patterns do not shift in a global way in 
response to Hiwi.  Moreover, the vast majority of piRNAs identified do not correlate to gene 
regions.  
  piRNAs have not been thoroughly studied in cancers, however a few preliminary 
studies suggest that individual piRNAs may be altered in cancers. A specific piRNA, piRNA 651, 
is aberrantly over-expressed in multiple cancers (gastric, colon, lung and breast cancer tissues), 
when compared with normal tissues [88].  Furthermore, inhibition of this piRNA in gastric cancer 
cell lines (another cancer in which Hiwi is over-expressed [69]) resulted in decreased cellular 
growth.  The growth inhibition effect of the piRNA antagonist was modest, but these data 
suggest that there may be an important potential role for aberrant piRNA expression in 
contributing to over-proliferation in cancer cells.  Individual piRNAs have also been detected in  
peripheral blood of patients with gastric cancer [89].    Two specific piRNAs, one of which was 
piRNA 651, were chosen for evaluation and both were significantly lower in peripheral blood 
from gastric cancer patients, compared to healthy controls, suggesting that piRNA detection 





to contrast with the report that piRNA 651 is increased in cancer tissues, however this may be 
reflective of the different tissues which were examined for piRNA 651 expression: cancer 
tissues versus peripheral blood.  Because these are only the first studies to examine piRNA 
expression levels in cancer, it is important to note that much more investigation is necessary, 
both to validate these studies and to identify piRNA expression in additional cancer types.  A 
more pressing issue is that these studies did not provide evidence for a global alteration of the 
piRNA population in cancer versus normal cells; rather they focused on one or 2 specific 
piRNAs which may or may not be indicative of the entire piRNA population.  There is no 
explanation of general piRNA changes which may be occurring, and no indication of what 
criteria were used to select individual piRNAs for further analysis.  There might be important 
changes occurring in the piRNA population as a whole in cancer versus normal tissues.    In 
order to more fully explore the potential role that piRNAs may play in cancer, it will be critical to 
examine global piRNA alterations in cancer tissues.  As a first step, it would be interesting to do 
a global bioinformatic profile of piRNAs in cancer versus normal tissues, just as has been done 
for miRNA profiles in cancer [133].  Perhaps in this way, we will be able to develop a piRNA 
“signature” which differentiates cancer versus normal [134,135].  Importantly, because no 
mechanistic insight into the role of piRNAs in cancer has been explored, it is not known if 
piRNAs might be driving tumorigenesis or if their alteration is merely a bystander effect that is 
part of the cell’s stem cell recapitulation process.  Our data suggest that, because they are 
present even in parental MSCs, they are not driving the tumorigenic process.  An important next 
step to identifying the functional role of piRNAs in cancer might be to perform transfection 
experiments with piRNAs of interest (or their antagoPIRs) and then monitor for tumorigenic 
growth (perhaps via colony forming or invasion assays).  The current limitation is the ability to 
choose a piRNA or set of piRNAs of interest to exogenously express in vitro, since so little is 





piRNAs have also been identified in HeLa cells [81].  Moreover, Hili, a human Piwi 
homolog, has also been identified in HeLa cells and its up-regulation results in decreased Line1 
transposon expression and decreased expression of piRNAs that are derived from Line1 repeat 
sequences.  Importantly, the overall number of piRNAs did not change significantly when Hili 
was expressed—in line with our data which does not show a global shift in piRNA populations in 
response to Hiwi expression.  
Based on data from a variety of model organisms where piRNA populations have been 
identified outside the germline, there may be a much wider expanse of piRNA populations 
across a variety of cell types, including both normal and cancer cells.  A well-defined aspect of 
piRNAs is their association with Piwi family members, which have been found at high levels, 
developmentally, in normal germline stem cells and, aberrantly, in a variety of cancers.  
Importantly, though, the presence of piRNAs in the absence of Piwi homologs suggests that 
their roles in cells might be broader than previously thought.  piRNAs may act with other 
proteins, perhaps members like their miRNA cousins, to exert their epigenetic silencing effects.   
Though Piwis are necessary for piRNA biogenesis, our work suggests that piRNAs may have a 
non-Piwi-related mechanism for biogenesis that has not yet been elucidated.   
Our work opens the possibility that piRNA populations are present in many cell types, 
but are only able to carry out their epigenetic silencing effects when there is also high 
expression of Piwi orthologs, such as in normal germline stem cells and in cancer cells.  In this 
way, piRNA expression, along with abundant Piwi expression, in germline stem cells results in 
normal transposon silencing during spermatogenesis via DNA methylation (Figure 5.1A).  The 
cells develop normally into somatic tissues in which Piwis are absent (Figure 5.1B). However, 
in a cancer context -- where Hiwi  is aberrantly highly expressed—the presence of both Piwi and 





including regions of tumor suppressor genes), which results in consequent tumorigenesis 
(Figure 5.1C) [136].  However, this model is highly speculative, as the exact role of piRNAs in 
cancer, and the mechanism by which they may be performing that role, remains largely 
unexplored both in cancer cell lines and in cancer tissues.  In order to further test this model, it 
will be critical to determine the exact mechanism(s) by which piRNAs exert their gene silencing 
effects.  Even in normal developmental systems, where piRNAs are best studied, a detailed 
mechanism of piRNA function remains elusive.  For example, it is unknown whether piRNAs are 
responsible for gene regulation (not just transposon repeats).  This remains especially 
understudied in a cancer context.  It will also be enlightening to know whether piRNAs are 
associated with any chromatin modifying proteins, such as DNMTs, histone methyltransferases, 
or histone acetyltransferases.  Additionally, Piwi proteins have been found to be associated with 
chromatin modifying proteins and with the chromatin itself [137].  This Piwi-chromatin 
association was indirectly shown to be RNA dependent.  While this work was done in 
Drosophila, it will be ideal to see if Hiwi co-localizes with any chromatin modifying proteins or 
with the chromatin itself in human cells.  Additionally, a co-localization experiment of piRNAs 
with the chromatin in MSCs will be useful to determine if piRNAs associate directly on the 
chromatin.  As investigators continue to resolve these outstanding issues, a model for piRNA 
function, both in the presence and in the absence of Piwi proteins, will become more clearly 






Hiwi-mediated tumorigenesis is associated with DNA methylation 
Once we had identified a novel oncogenic role for Hiwi as a driver of tumorigenesis, we then 
sought to investigate a mechanism by which Hiwi mediates its sarcomagenic effects.  In 
Chapter 4, we use Hiwi over-expression and knockdown models, along with human primary 
sarcoma samples, to show that global DNA methylation levels correlate with Hiwi, that DNA 
methyltransferases (DNMTs; DNMT1, DNMT3a, MDB2) are up-regulated in Hiwi-MSCs and that 
global DNA methylation increases are reversible upon treatment with a DNA de-methylating 
 
Figure 5.1 A potential model for Piwi and piRNA function in normal development 
and in cancer 
(A)  In germline stem cells, the presence of piRNAs and high Piwi levels, along with other 
chromatin modifying agents, results in DNA methylation to silence transposons. (B) 
During normal development (green arrow), Piwis are absent and the epigenetic marks of 
differentiated somatic cells allow for transcription of genes that maintain cells in a 
differentiated state, including reduced DNA methylation (C) piRNAs may be present in a 
variety of cell types.  However, when Piwi orthologs are highly expressed, there is 
aberrant over-methylation and over-silencing of the genome, perhaps including tumor 
suppressor genes.  This results in aberrant “stem like” epigenetic state (red arrow) and 






agent, 5-azacytidine.  Moreover, 5-azacytidine treatment mimics knock down of Hiwi, in both 
decreased colony forming capacity and in the gene expression changes that occur.  To further 
elucidate a DNA methylation-based mechanism for Hiwi-mediated tumorigenesis, we used gene 
expression overlapping to identify tumor suppressor genes which are altered in response to Hiwi 
expression and are also methylation dependent.  In particular, we identified cell cycle dependent 
kinase inhibitors (CDKIs; p21, p27,p15) as having a tight inverse correlation with Hiwi 
expression in human sarcoma samples.  CDKIs are a known class of tumor suppressors, as 
they prevent the cell from entering the cell cycle at cell cycle checkpoints when DNA damage 
has occurred [138,139,140].  Moreover, CDKIs are thought to be amenable to epigenetic 
regulation, especially in cancers such as ovarian cancer, leukemia, and lymphoma 
[141,142,143]. Since many cancers show an increase in methylation of CDKIs as an epigenetic 
mechanism for their down-regulation in cancer, CDKIs are likely a subset of tumor suppressor 
genes which are affected by Hiwi-associated DNA methylation and tumorigenesis.      
We also investigated the promoter CpG methylation status of doxycycline-induced sh-Hiwi-
MFH and find that promoter methylation does not shift globally upon Hiwi down-regulation. 
Moreover, bisulfite sequencing of the Rb1 and Line1 promoters shows no significant changes in 
promoter methylation as Hiwi levels change.  Taken together, our data reveal that Hiwi-
mediated tumorigenesis is associated with DNA methylation increase, though not at CpG 
promoter regions.  This results in silencing of tumor suppressor genes, perhaps including 
CDKIs, and consequent tumorigenesis.  Our data also suggest a novel therapeutic avenue for 
epigenetic agents in the treatment of Hiwi-expressing cancers.  
Despite the tight correlations between Hiwi expression, global DNA methylation, and 
tumorigenesis described here, there are still several open questions which merit further 
investigation.  The first is the determination of the exact cellular location of Hiwi. In our models 





DNA methylation suggests that it is influencing nuclear proteins as well.  We have thus far been 
unable to identify Hiwi localized to the nucleus.   While we are limited by the number of 
commercially available antibodies for Hiwi, we have tried both immunohistochemical and 
western blotting approaches to identify nuclear Hiwi.  However, others have also identified 
cytoplasmic Piwi homolog expression, so we believe our results are not simply due to technical 
difficulty.  In one model, Hiwi may be shuttled in and out of the nucleus, although a majority 
remains in the cytoplasm and that is what has been detected thus far.  Another model is that 
Hiwi uses intermediary proteins (such as DNMTs) to exert its DNA methylation-based silencing 
effects.  In order to test the shuttling hypothesis, perhaps a fluorescent-tagged Hiwi can be 
transfected into cells and then followed so that its localization can be tracked via live microscopy 
from the cytoplasm to the nucleus.  The association of Piwi homologs with chromatin modifying 
proteins has been examined by others [137,144].  Thus it would not be totally surprising if Hiwi 
also associated with a DNMT protein.  However, this must be experimentally determined, such 
as through an IP-mass spectrometry experiment, where Hiwi and its associated proteins are 
pulled out and the Hiwi-associated complex is identified via a mass spectrometry approach.  We 
have begun experiments to identify Hiwi binding partners using a yeast 2-hybrid approach. 
We have shown that DNMT1, DNMT3a and MDB2 are up-regulated in Hiwi-MSCs, but they 
are up-regulated translationally; their RNA levels do not change in either Hiwi-MSCs (compared 
to parental MSCs) or in sh-Hiwi-MFH sarcoma cells (either before or after doxycycline induction 
to knockdown Hiwi levels).  The exact mechanism by which high levels of Hiwi expression may 
promote translational up-regulation of DNMTs is still unclear.  However, DNMTs are known to 
be regulated by post-transcriptional modifications and by small RNAs [145], so it is plausible 
that Hiwi promotes the post-transcriptional regulation of DNMTs.  Our data, along with work 
from others which shows that Miwi (murine Piwi ortholog) interacts with ribosomes [122], 





translation.  In order to more fully explore a mechanism of Hiwi-associated translational up-
regulation of DNMTs, an assessment of the stabilizing post-translational modifications of 
DNMTs should be done.  This includes acetylation and de-ubiquitination [146], although other 
stabilizing post-translational modifications might also be regulating DNMTs in our Hiwi-MSCs 
compared to parental control MSCs.  We are continuing to investigate the exact relationship 
between Hiwi and its epigenetic mechanisms in a cancer context, and many other laboratories 
are investigating this relationship in a developmental context [2,28,29,30,36,55,58,59,60]. 
The relationship between Piwi orthologs and DNA methylation has been better studied in 
mice [55,59], yet the exact mechanism of Piwi-mediated DNA methylation during development 
is still unclear.  Our data showing that although global DNA methylation correlates with Hiwi 
levels, promoter CpG methylation does not change during Hiwi down-regulation, suggesting that 
Hiwi-associated DNA-methylation occurs globally at non-CpG promoter areas and/or at 
repetitive element regions.  Confirming this interpretation, our bisulfite sequencing of either the 
Line1 element or the Rb1 promoter shows no change in DNA methylation at those sites as Hiwi 
levels change.  Repetitive element methylation has previously been reported to result in long 
distance silencing via chromatin remodeling [123,124].  Since Piwis are thought to associate 
with piRNAs that have homology to repetitive elements [61,125], this may explain why promoter 
methylation is not altered as Hiwi expression is altered in our systems.  
Recently,  Piwi homolog, Hiwi2, was implicated in p16 silencing through histone methylation 
rather than gene promoter methylation [119].   We then examined a number of histone 
methylation marks in our sh-Hiwi-MFH cells via immunofluorescence (IF) but found no alteration 
of these chromatin marks.  Although we agree that promoters of silenced genes will display 
associated repressive chromatin marks, in our studies, we have been unable to identify these 
changes (at neither promoter DNA nor histone methylation).  As an initial screen, we examined 





further investigate, we did not continue this line of investigation with other experimental 
approaches.  However, a more exhaustive screen of all chromatin marks (histone acetylation, 
phosphorylation), not just histone methylation, might yield additional information regarding Hiwi-
mediated epigenetic mechanisms of gene silencing, since it is thought that many chromatin 
modifying marks work in concert to induce chromatin changes [112].  The most common 
repressive chromatin changes, promoter methylation and the only one previously reported to be 
associated with Piwi orthologs, histone methylation, were not identified.      
It is widely accepted that global DNA methylation levels are decreased in many human 
cancers, despite increases in specific CpG island methylation (at both promoter and non-
promoter regions).  In this way, global hypo-methylation in cancer is thought to occur at 
repetitive elements, which make up a substantial portion of the genome (reviewed in [128,129] ) 
Our data that Hiwi-associated DNA methylation increases as Hiwi expression increases is 
somewhat discordant with this generally accepted notion.  However, Piwi homologs have a 
preference for silencing repetitive regions via DNA methylation during normal development, 
suggesting that Hiwi may target silencing of repetitive regions via DNA methylation in cancer 
cells, thus providing a mechanistic understanding of Hiwi’s exception to the widely observed 
phenomenon of global hypo-methylation in cancer.    
The role of Hiwi in adult neoplastic tissues remains fertile ground for further investigation, 
despite our studies which define a novel oncogenic role for Hiwi and reveal that tumor 
suppressor gene silencing via DNA methylation mechanistically accounts for this tumorigenesis.  
We further suggest that the use of epigenetic agents, such as 5-azacytidine, in the treatment of 
cancers which have high levels of Hiwi would be clinically beneficial.  Because DNA de-
methylating agents are currently used to treat myelodysplastic disorders and acute myeloid 
leukemia [111], many issues regarding patient safety have already been addressed.  So our 





tumors is both reasonable and feasible.  In fact, many clinical trials for DNA de-methylating 
agents in the treatment of a variety of diseases (including colorectal cancer, lymphoma, 
squamous cell carcinoma) are on-going.   
Model for Hiwi-mediated tumorigenesis 
Through in vitro and in vivo models of Hiwi over-expression and down-regulation, we 
have shown that Hiwi is a driver of tumorigenesis and is associated with global DNA hyper-
methylation.  Importantly, this increase in DNA methylation occurs at non-promoter CpG regions 
and is reversible with DNA de-methylating agent treatment.  A class of epigenetically-regulated 
tumor suppressor genes (CDKIs) has a tight inverse correlation with Hiwi in primary sarcomas.  
Synthesizing these mechanistic data, we can develop a working model in which Hiwi is 
aberrantly up-regulated in cancer, leading to an increase in global DNA methylation, perhaps 
through translational stabilization of DNMTs.  This global DNA methylation silences non-
promoter CpG regions, including tumor suppressor genes such as CDKIs, resulting in Hiwi-
mediated tumorigenesis. This model fits our data nicely, but there are still mechanistic details 
which need to be resolved if we are to generate a precise and detailed model of Hiwi-mediated 
tumorigenesis.  One of those missing mechanistic details is the exact proteins which Hiwi is 
binding to in order to promote DNA methylation at non-promoter CpG regions.    
In order to address this issue, we have undertaken a yeast 2-hybrid approach to identify 
any Hiwi binding partners (Dr. Katrin Rutschmann, Dualsystems Inc.).  Hiwi was cloned into a 
bait vector and screened against a cDNA library generated from MFH sarcoma cells, the same 
cell line used in our doxycycline-induced sh-Hiwi-MFH model.  The yeast 2 hybrid revealed only 
one Hiwi binding partner which was rescued multiple times (rescue multiple times is suggestive 
of a true protein-protein interaction).  This binding partner is histone variant H3.3 (Figure 5.2).  





preliminary data suggesting Hiwi and H3.3 binding must still be independently confirmed using 
an immunoprecipitation-immunoblot (IP-IB) approach, since yeast 2-hybrid can be highly 
sensitive and thus physiologically irrelevant. Because commercially available Hiwi antibodies 
are not suitable for IP purposes, we have taken a tagging approach to these IP-IB experiments, 
using a HA-tagged Hiwi vector and a myc-tagged H3.3 vector.  Co-transfection of these vectors 
into cells, then IP-IB for a Hiwi-H3.3 interaction using antibodies against the distinct molecular 
tags rather than the proteins directly is a straightforward method to circumvent a lack of 
appropriate commercial antibodies.  IP-IB confirmatory experiments are on-going in our lab. 
     
In light of these preliminary yeast 2-hybrid data indicating H3.3 is a Hiwi binding partner, 
we can update our working model for Hiwi-mediated tumorigenesis via DNA methylation to 
include H3.3 as a modulator of transcription (Figure 5.3A).  In cancer cells which aberrantly 
 
Figure 5.2 Yeast 2-hybrid results indicate H3.3 is a Hiwi binding partner 
Histone variant H3.3 was the only protein to be rescued multiple times in the yeast 2-
hybrid assay, suggesting it is a true Hiwi-interactor.  These data must be confirmed 







express Hiwi at high levels, Hiwi directs DNA methylation, though this is limited to CpGs at non-
promoter regions.  Hiwi interacts with H3.3, as the yeast 2-hybrid data suggest, at sites of active 
transcription in order to mediate transcriptional shut off.   There are emerging data which 
suggest that H3.3, previously associated only with sites of active transcription, may also 
accumulate at silent loci, in both stem cells [148,149] and in somatic cells [150].  It is possible 
then, that H3.3 enrichment is indicative of a poised chromatin state [151], rather than only active 
transcription.  These data are in line with our model, which proposes that Hiwi expression is 
associated with silencing via DNA methylation.  In our model, Hiwi may bind H3.3 at sites of 
poised transcription, thus encouraging transcriptional repression rather than activation.  
Whether Hiwi recruits H3.3 to genomic regions which will be silenced or whether H3.3 is already 
present at baseline levels is still unknown, although our gene expression analyses find that H3.3 
is present at very low baseline levels at MFH cells (But to the best of our knowledge, there has 
been no systematic investigation of H3.3 expression in primary human sarcomas). At the same 
time, Hiwi expression correlates with translational stabilization of DNMTs, further promoting 
silencing of the genome via DNA methylation.  Translational stabilization of DNMTs has been 
established via de-acetylation and de-ubiquitination [146], including in a cancer context [152].  
Since DNMTs were not found to be Hiwi binding partners via yeast 2-hybrid screening, it is likely 
that Hiwi promotes stabilization of DNMTs via intermediaries that interact with DNMTs.  These 
might include deacetylases, ubiquitin proteases, and other stabilizing proteins which make up a 
multi-protein complex associated with the DNMT [153]. In this way, Hiwi may be able to stabilize 
DNMTs translationally without a direct interaction with DNMTs.  The DNMTs then go on to 
methylate DNA at non-promoter CpG regions.  Importantly, because promoter methylation 
status does not change, DNA methylation seems to be directed outside promoters, though its 
exact locations are still under investigation in our lab.  It is possible that Hiwi is working, through 





machinery that is local to the sites of methylation.  Long distance epigenetic silencing is an 
established regulatory phenomenon in which methylation-based silencing occurs at large 
regions, rather than at discrete promoter sites [124].  Long distance methylation has been 
implicated in both normal development [154] and in cancers [155] and likely occurs in 
conjunction with local histone (de-) acetylases, histone methyltransferases and other epigenetic 
remodeling proteins to induce silencing of non-promoter CpG regions [155].  Methylation 
associated with long distance silencing may also occur regardless of the euchromatic or 
heterochromatic regions of the genes [123], in line with our data which suggest that Hiwi 
interacts with H3.3, a histone known to be at sites of poised chromatin.  Recent work also 
suggests that in cancer, non-promoter CpGs may be more susceptible to methylation compared 
to normal cells [156].  In our model, due to increased DNA methylation, tumor suppressor genes 
are aberrantly silenced, which results in tumorigenesis.  We specifically examined CDKIs and 
found them to be poorly expressed in Hiwi-expressing primary sarcomas.  Our model is the first 
to examine an epigenetic mechanism regulating Hiwi-mediated tumorigenesis.    
A remaining question in this working model is the exact location of Hiwi during the 
tumorigenic process.  As mentioned earlier, our data and that from other groups [73,121], 
suggest that Hiwi is cytoplasmic.  However, given the evidence that Hiwi is associated with DNA 
methylation, it is possible that Hiwi is shuttled into the nucleus, although we have been unable 
to consistently detect significant amounts of nuclear Hiwi in our IHC assays.  Alternatively, 
cytoplasmic Hiwi might be using an intermediary (or set of intermediaries) to promote the 
stabilization of DNMTs (as described above).  Stabilized DNMTs then go on to methylate DNA. 
Our yeast 2-hybrid data would suggest the former, although the 2 theories are not mutually 
exclusive.  Further investigation of Hiwi localization might be undertaken using a western blot 
approach of Hiwi using nuclear and cytoplasmic separated cellular samples.  An IF approach 





were limited by the availability of commercial antibodies appropriate for western blotting and IF.  
It may be necessary, therefore, to generate a new model for Hiwi over-expression, in which a 
tagged version of Hiwi is stably transfected/infected into sarcoma progenitor MSCs.  By taking 
advantage of the wide availability of antibodies against tags (GFP, myc, flag, HA, etc), many 
experiments which are limited by Hiwi antibodies may be performed, including an IF analysis of 
Hiwi localization, protein-protein interactions and chromatin immunoprecipitations.  A potential 
disadvantage of this approach is that the attached tag disrupts Hiwi’s cellular 
function/localization.  This risk can be minimized by using a tag that is relatively small, such as a 
flag tag. Similarly, a tagged transgenic mouse model for Hiwi over-expression may also be 
useful in order to track Hiwi expression during tumor development (This is discussed further in 
the following section.).      
Our developing model for Hiwi mediated tumorigenesis suggests that Hiwi is a driver of 
tumorigenesis, via stabilization of DNMTs, and increased global DNA methylation.  This results 
in silencing of tumor suppressor genes and results in tumorigenesis.  Ours are the first data to 








The next generation of transgenic mouse models of Hiwi over-expression 
 In Chapter 2, we describe the generation of an appendicular, mesoderm-specific 
transgenic mouse model of Hiwi over-expression.   Because no relevant sarcoma mouse 
models have been generated to date, this was an important investigational tool which we 
developed. This model uses the Prx1 enhancer element to drive the expression of Hiwi in the 
developing limb bud mesoderm only.  After careful monitoring and analysis of these mice for 
over 2 years, we find that the tumor incidence rate is below 10%, although the tumors that do 
develop are in the expected distribution (on the limbs).    
 
Figure 5.3 A working model for Hiwi-mediated tumorigenesis 
(A) Hiwi is aberrantly up-regulated in cancer cells, leading to an increase in DNA 
methylation through the translational stabilization of DNMTs.  This silences tumor 
suppressor genes, which results in tumorigenesis.  (B) Treatment with 5-azacytidine 
decreases global DNA methylation, allowing for the expression of tumor suppressor 






One explanation for this low tumor incidence rate might be that Hiwi over-expression 
alone is not sufficient to form tumors at a high rate in a transgenic mouse model.  Importantly, 
the Prx1 enhancer element has been used to specifically delete the Rb1 tumor suppressor gene 
in Prx1 tissues [92].  These Rb1-deleted mice do not form sarcomas at all and are ostensibly 
normal.  In order to test the possibility that Hiwi over-expression, in combination with tumor 
suppressor gene loss, will result in a higher tumor incidence rate, we are currently generating 
Prx1-Hiwi+; Prx1-Rb1-/- mice.  Given the aforementioned data on Prx-Rb1, we would expect 
that while Hiwi is sufficient to initiate sarcoma formation (albeit at a low rate), Rb is not.  Rather, 
Rb1 might contribute to the acceleration of sarcoma formation or sarcoma maintenance, once 
another initiating mutation is introduced (described for Prx1-p53-/-;Prx1-Rb1-/- mice in [92]).  In 
this way, we expect that Prx1-Hiwi+; Prx1-Rb1-/- mice will contain both initiating (Hiwi over-
expression) and acceleration (Rb1 loss) events, which will result in an increased tumor 
incidence rate.  This work is on-going in our lab. We anticipate this transgenic mouse model to 
be a more accurate recapitulation of human sarcomas than those currently used. This mouse 
model might also be useful in studying therapeutic avenues for sarcomas pre-clinically, since 
many human sarcomas have Rb1 mutations [157].  This, in combination with our data that find 
Hiwi to be highly expressed in human sarcomas, suggest that a Prx1-Hiwi+; Prx1-Rb-/- 
transgenic mouse model would be highly relevant in recapitulating human sarcomas. 
 Another explanation of the low tumor incidence rate we find in our Prx1-Hiwi transgenic 
mouse model is that perhaps the promoter is simply too weak to drive the expression of Hiwi as 
robustly as necessary for Hiwi levels to reach a critical threshold beyond which tumors form.  To 
assess this, we are currently generating a transgenic mouse model of Hiwi over-expression, 
where Hiwi is driven by a multisite pCAGG- promoter (targeted to the ROSA26 locus) which has 
floxed-stop alleles.  Upon introduction of Prx1-Cre to the system (to ensure only mesodermally-





pCAGG, known to be 8 to 10 fold stronger than the pROSA26 promoter, based on transgene 
expression [158].  Additionally, the multisite pCAGG vector contains a GFP tag C-terminal to the 
Hiwi cDNA, as a method to visualize Hiwi expression in any tumors which develop.  Using this 
approach, we hope to generate mesoderm-specific Hiwi -over-expression in our mouse model 
that is much higher than that of the Prx1-Hiwi mouse model.  This work is continuing in our lab.   
  
A novel therapeutic avenue for Hiwi-expressing tumors 
In Chapter 3, we observe that 5-azacytidine treatment is able to reverse the increased 
global DNA methylation found in Hiwi-MSCs.  Moreover, 5-azacytidine-treated sh-Hiwi MFH 
cells show decreased colony formation capacity that is very similar to what is seen during 
doxycycline-induced knock down of Hiwi.  We go on to show that the gene expression changes 
of both 5-azacytidine treated cells and doxycycline-induced Hiwi knock down cells are very 
similar, with a high degree of overlapping gene changes.  These data suggest that 5-azacytidine 
treatment and Hiwi knock down might be working through similar mechanisms to reduce the 
colony forming capacity of MFH sarcoma cells. Because 5-azacytidine has already been used 
for treatment of acute myeloid leukemia and myelodysplastic syndromes [111], our suggestion 
that 5-azacytidine may also be used to treat Hiwi-expressing cancers is clinically feasible, since 
toxicity issues have already been vetted.  Importantly, though, 5-azacytidine in the treatment of 
Hiwi-expressing cancers might be beneficial at lower doses which modify DNA methylation 
rather than the higher doses used in myelodysplastic syndrome treatment which induce cell 
death [112].  
We are able to integrate these data into our working model of Hiwi-mediated 
tumorigenesis: treatment with 5-azacytidine decreases global DNA methylation levels and tumor 





(Figure 5.3B).  In both colony formation and in gene expression profiles, treatment of sarcoma 
MFH cells with 5-azacytidine seems to mimic Hiwi knock down in sarcoma MFH cells. This 
leads us to suggest that the use of DNA de-methylating agents might be clinically relevant to 
treating cancers.  Tumors which express Hiwi at high levels (sarcomas, but also a variety of 
other cancers [65,66,67,69,95]) might be particularly sensitive to treatment with epigenetic 
agents such as 5-azacytidine.  Just as Her2 expression is used as a marker for identifying 
breast cancers which are might be particularly sensitive to Herceptin treatment [159], Hiwi 
expression might also be used as a marker to identify cancers which would be most sensitive to 
epigenetic therapies.  Our data are the first to suggest a therapeutic rationale for the use of 
epigenetic agents in the treatment of Hiwi-expressing cancers.   
Potential global implications of our studies 
Work from a variety of labs implicates Piwi family proteins in the silencing of transposon 
repeats during normal development of the germline.  At the same time, Hiwi, the human 
homolog of Piwi, has been found to be elevated in a variety of cancers, including sarcomas.  
However, a potential connection between Hiwi and sarcomagenesis remained unexplored 
before we started the studies described here.  We have demonstrated for the first time a 
causative oncogenic role for Hiwi as a driver of sarcomagenesis.  Moreover, we have found that 
Hiwi levels correlate with global DNA methylation levels and DNMT expression levels.  Hiwi has 
a tight inverse correlation with a class of tumor suppressor genes, cell cycle dependent kinase 
inhibitors (CDKIs).  These data are the first to implicate DNMTs in the mechanism behind Hiwi-
mediated DNA methylation and silencing, either in normal development or in cancer.  Our 
studies open a new direction for the study of the exact role of DNMTs in the epigenetic 
mechanisms behind Hiwi-mediated tumorigenesis and also Hiwi-mediated transposon silencing 
in the normal germline.  These data also implicate non-promoter CpG methylation as a regulator 





identify tumor suppressor genes which are aberrantly regulated by Hiwi expression (although 
indirectly), we have established the first set of genes, rather than repetitive elements, which are 
sensitive to Hiwi expression.   Together, our data suggest a mechanism for Hiwi-mediated 
tumorigenesis in which Hiwi promotes DNA methylation and tumor suppressor gene silencing.  
Ours are the first reports to provide mechanistic insight into Hiwi’s role in human cancers.  Ours 
are also the first reports to suggest a therapeutic rationale for clinically treating Hiwi-expressing 
cancers with epigenetic agents such as 5-azacytidine.   
Aside from revealing an oncogenic role for Hiwi and its mechanistic basis in human 
cancers, we have also identified piRNAs in our MSCs, in the absence of Piwi homolog 
expression.  Our data are in line with that from other groups which suggest that piRNAs may be 
expressed much more broadly than previously thought.  piRNAs have been found in many 
tissues outside the germline, including in some human cancers.  Our data also have 
implications for the field of piRNA biogenesis.  Without Piwi expression, piRNAs may use some 
alternative non-ping-pong based generation mechanism, but what this might be remains 
unexplored.  Alternatively, there may be a novel Piwi homolog that has yet to be identified and 
this Piwi homolog is mediating piRNA biogenesis in MSCs.  Additionally, the majority of piRNAs 
we identified do not map to gene regions, which is in keeping with the known homology of 
piRNAs in a variety of model organisms to repetitive regions rather than genes. 
Taken together, our data underscore the importance of Hiwi expression as a driver of 
tumorigenesis and reveal mechanistically that Hiwi-associated DNA methylation silences tumor 
suppressor genes to mediate tumorigenesis.  Our work has implications for the basic biology of 
Piwi protein/piRNA function, for the epigenetic control of gene expression and also for cancer 
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